改善心力衰竭预后的相关研究
|
摘要
IC53基因自身抗体与心力衰竭预后关系的研究
背景：心力衰竭是大多数心脏疾病的终末临床表现。心衰的发病机制、病理生理变化十分复杂，目前仍未完全阐明。越来越多的研究证实，自身免疫反应参与了心衰的病理生理过程，在心衰的发生发展中起着很重要的作用。心衰病人外周血中可以检测到多种抗心脏自身抗体，这些自身抗体与心衰有着密切关系。本研究主要检测扩张性心肌病、冠心病心衰病人中IC53基因自身抗体水平，分析IC53基因自身抗体对心血管终点事件的影响以及与心衰预后的关系。旨在为临床预测、诊断及治疗心力衰竭提供新的诊断试剂或药物作用新靶点。
方法：1.研究样本包含特发性扩张型心肌病心衰病人177例，冠心病心衰病人588例。2.以合成肽作为抗原，应用酶联免疫吸附测定技术检测两组受试者血浆中IC53自身抗体。3.平均随访4年，终点事件是心源性死亡和猝死。4.应用Cox回归分析和Kaplan-Meier分析IC53基因自身抗体水平与心力衰竭终点事件的关系。
结果：在177例扩张型心肌病中IC53自身抗体阳性率为18.6%，在580例冠心病心衰中为24.1%。平均4年（0.4个月―78个月）的随访中，扩张型心肌病总死亡人数76人，死亡率为42.9%。其中IC53自身抗体阳性病人的死亡数是20人，死亡率为60.6%；自身抗体阴性病人的死亡数是56人，死亡率38.9%。冠心病心衰总死亡人数159人，死亡率为27.1%。其中IC53自身抗体阳性病人的死亡数40人，死亡率为28.6%；自身抗体阴性病人的死亡数119人，死亡率26.6%。我们应用Cox回归分析方法，修正了年龄、性别、以及对终点事件的可能风险因素，分析结果显示扩心病组，IC53抗体阳性病人的死亡率明显高于抗体阴性病人的死亡率，具有明显统计学差异（P=0.010，OR=1.96,95%CI：1.17-3.28）；冠心病组，IC53抗体阳性病人的死亡率与抗体阴性病人的死亡率相似，无统计学差异（P=0.933，HR=1.02,95%CI：0.71-1.46）。应用时间等级检验方法，对扩心病组抗体阳性和阴性病人生存时间制作了Kaplan–Meier曲线，结果显示抗体阳性病人的生存率明显低于抗体阴性病人的生存率。
结论：扩张型心肌病心衰病人及冠心病心衰病人血浆中存在IC53基因自身抗体。IC53基因自身抗体增加扩张型心肌病死亡风险，而与冠心病心衰死亡终点无关。IC53基因自身抗体阳性可以作为扩张型心肌病心衰的独立预警信号。
急性冠脉综合症急诊介入治疗冠脉内与静脉内注射
糖蛋白ⅡbⅢa抑制剂的比较：一个随机对照临床研究的荟萃分析
背景：急性冠脉综合征患者行经皮冠状动脉介入治疗（PCI）时，冠脉内（IC）注射IIb/IIIa糖蛋白抑制剂(GPIs)的给药途径是否优于静脉注射(IV)，目前仍然存在争议。
方法：我们对比较两种给药途径的随机对照临床研究进行了一个荟萃分析。研究的主要终点是短期(1-3个月)和中长期(6-12个月)主要心血管不良事件(MACEs)(死亡率,再梗死率、靶血管血运重建)。次要终点是术后TIMI血流、TMPG血流分级，术后2周左心室射血分数（LVEF），出血并发症。
结果：12项临床研究被纳入荟萃分析。同静脉内使用GPIs相比，冠脉内给药并没有减少短期死亡率(OR:0.71,95%CI:0.41-1.23, P=0.22）和再梗死率（OR:0.76,95%CI:0.45-1.29, P=0.31)。IC组同IV组相比，其短期TVR率呈下降趋势，但没有统计学意义的差异（OR:0.57,95%CI:0.31-1.04, P=0.07）。同静脉内给药相比，冠脉内注射GPIs明显增加了TIMI3级血流（OR:1.48,95%CI:1.06-2.06, P=0.02）和TMPG2-3级血流（OR:2.63,95%CI:1.53-4.51, P=0.0004）。中长期MACEs发生率、LVEF和出血并发症在两组之间无明显差异。
结论：急性冠脉综合征患者PCI治疗时，冠脉内直接注射GPIs比静脉注射大大增加靶血管血流量和心肌再灌注，且不增加出血风险，但对临床预后的改善并不优于静脉给药。
Association between Autoantibody againstIC53Gene and Prognosis of Patients with Heart Failure
Background: Heart failure (HF) is the final clinical entity of many diverse diseasecauses and mechanisms. During the last years, it has been discovered that autoimmunity playsan important role in the progression and induction of heart failure. Circulating autoantibodies,some of them being heart-specific, have been critically linked to heart failure. The objectiveof study is to determine whether autoantibody against IC53gene is related to prognosis ofpatients with heart failure.
Methods: The study included588patients with HF caused by coronary artery disease（CAD） and177patients with HF caused by dilated cardiomyopathy (DCM). Based onsynthetic peptides as antigens, enzyme-linked immunosorbent technique was used firstly todetect the antibody against IC53in serum of the patients. The study population was followedup for a median period of4years until December2013. The end points included cardiac deathand sudden cardiac death (SCD). We performed survival analysis in the HF population. HRs(hazard ratios) for time to cardiac death and SCD from baseline were estimated using Coxproportional hazards models. we analysed Kaplan–Meier curves for time to probability ofsurvival using the log rank test according to positive or negative of antibody against IC53inthe patients with DCM.
Results The positve rates of serum for IC53gene were18.6%and24.1%in CHFpatients with DCM and patients with CAD. During a median follow-up period of4years(range,0.4–78months), mortality of patients with DCM was42.9%and mortality ofpatients with CAD was27.1%. Mortality of patients with positive antibody against IC53genein DCM team was60.6%; mortality of patients without positive antibody against IC53gene inDCM team was38.9%. Mortality of patients with positive antibody against IC53gene inCAD team was28.6%; Mortality of patients without positive antibody against IC53gene inCAD team was26.6%. After adjustment for age, gender and suspected risk factors by using asurvival Cox regression analysis, positive antibody against IC53gene in the patients with DCM had an increased risk of cardiac death compared with negative of antibody against IC53in the patients with DCM（P=0.010，HR=1.96,95%CI：1.17-3.28）. Positive antibody againstIC53gene in the patients with CAD had no increased risk of cardiac death compared withnegative of antibody against IC53in the patients with IHD (P=0.933，OR=1.02,95%CI：0.71-1.46).
Conclusion: Our results indicated that autoantibody against IC53gene can be detectedin patients with HF. Autoantibody against IC53gene can increase risk of cardiac death in HFcaused by DCM, and serves as an independent predictor of cardiac death.
A Comparison of Intracoronary with Intravenous GlycoproteinⅡb/Ⅲa Inhibitors during Percutaneous Coronary Intervention in Patientswith Acute Coronary Syndrome：A Meta-analysis of Randomized
Controlled Trials.
Background-It is still debatable whether intracoronary(IC) administration ofglycoprotein IIb/IIIa inhibitors (GPIs) is superior to intravenous (IV) administration forpatients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention(PCI).
Methods-We performed a meta-analysis of randomized controlled clinical trials. Aliterature search was conducted for relevant trials. Primary end points were short-term (1-3months) and mid-/long term (6/12months) major cardiovascular adverse events(MACEs)(mortality, re-infarction, target vessel revascularization). Secondary end points wereThrombolysis In Myocardial Infarction (TIMI) grade flow, TIMI myocardial perfusion grade(TMPG) flow, left ventricular ejection fraction (LVEF) within2weeks, bleedingcomplication.
Results-Twelve studies were included in the meta-analysis. IC administration of GPIsdid not decrease short-term mortality (OR:0.71,95%CI:0.41-1.23, P=0.22) andre-infarction rate (OR:0.76,95%CI:0.45-1.29, P=0.31) compared with IV administration.There was a trend towards reduction of short-term TVR rate in IC group compared with IVgroup but not reached statistical significance (OR:0.57,95%CI:0.31-1.04, P=0.07). ICadministration of GPIs significantly increased TIMI grade3flow (OR:1.48,95%CI:1.06-2.06, P=0.02) and TMPG grade2-3flow (OR:2.63,95%CI:1.53-4.51, P=0.0004)compared with IV administration. No significant difference was observed in long-termMACEs rate, LVEF and bleeding complication between the2groups.
Conclusion-IC administration of GPIs in patients with ACS undergoing PCI cansignificantly increase target coronary flow and myocardial reperfusion without increasing the risk of bleeding complication, but can not improve clinical outcome compared with IVadministration.
背景：心力衰竭是大多数心脏疾病的终末临床表现。心衰的发病机制、病理生理变化十分复杂，目前仍未完全阐明。越来越多的研究证实，自身免疫反应参与了心衰的病理生理过程，在心衰的发生发展中起着很重要的作用。心衰病人外周血中可以检测到多种抗心脏自身抗体，这些自身抗体与心衰有着密切关系。本研究主要检测扩张性心肌病、冠心病心衰病人中IC53基因自身抗体水平，分析IC53基因自身抗体对心血管终点事件的影响以及与心衰预后的关系。旨在为临床预测、诊断及治疗心力衰竭提供新的诊断试剂或药物作用新靶点。
方法：1.研究样本包含特发性扩张型心肌病心衰病人177例，冠心病心衰病人588例。2.以合成肽作为抗原，应用酶联免疫吸附测定技术检测两组受试者血浆中IC53自身抗体。3.平均随访4年，终点事件是心源性死亡和猝死。4.应用Cox回归分析和Kaplan-Meier分析IC53基因自身抗体水平与心力衰竭终点事件的关系。
结果：在177例扩张型心肌病中IC53自身抗体阳性率为18.6%，在580例冠心病心衰中为24.1%。平均4年（0.4个月―78个月）的随访中，扩张型心肌病总死亡人数76人，死亡率为42.9%。其中IC53自身抗体阳性病人的死亡数是20人，死亡率为60.6%；自身抗体阴性病人的死亡数是56人，死亡率38.9%。冠心病心衰总死亡人数159人，死亡率为27.1%。其中IC53自身抗体阳性病人的死亡数40人，死亡率为28.6%；自身抗体阴性病人的死亡数119人，死亡率26.6%。我们应用Cox回归分析方法，修正了年龄、性别、以及对终点事件的可能风险因素，分析结果显示扩心病组，IC53抗体阳性病人的死亡率明显高于抗体阴性病人的死亡率，具有明显统计学差异（P=0.010，OR=1.96,95%CI：1.17-3.28）；冠心病组，IC53抗体阳性病人的死亡率与抗体阴性病人的死亡率相似，无统计学差异（P=0.933，HR=1.02,95%CI：0.71-1.46）。应用时间等级检验方法，对扩心病组抗体阳性和阴性病人生存时间制作了Kaplan–Meier曲线，结果显示抗体阳性病人的生存率明显低于抗体阴性病人的生存率。
结论：扩张型心肌病心衰病人及冠心病心衰病人血浆中存在IC53基因自身抗体。IC53基因自身抗体增加扩张型心肌病死亡风险，而与冠心病心衰死亡终点无关。IC53基因自身抗体阳性可以作为扩张型心肌病心衰的独立预警信号。
急性冠脉综合症急诊介入治疗冠脉内与静脉内注射
糖蛋白ⅡbⅢa抑制剂的比较：一个随机对照临床研究的荟萃分析
背景：急性冠脉综合征患者行经皮冠状动脉介入治疗（PCI）时，冠脉内（IC）注射IIb/IIIa糖蛋白抑制剂(GPIs)的给药途径是否优于静脉注射(IV)，目前仍然存在争议。
方法：我们对比较两种给药途径的随机对照临床研究进行了一个荟萃分析。研究的主要终点是短期(1-3个月)和中长期(6-12个月)主要心血管不良事件(MACEs)(死亡率,再梗死率、靶血管血运重建)。次要终点是术后TIMI血流、TMPG血流分级，术后2周左心室射血分数（LVEF），出血并发症。
结果：12项临床研究被纳入荟萃分析。同静脉内使用GPIs相比，冠脉内给药并没有减少短期死亡率(OR:0.71,95%CI:0.41-1.23, P=0.22）和再梗死率（OR:0.76,95%CI:0.45-1.29, P=0.31)。IC组同IV组相比，其短期TVR率呈下降趋势，但没有统计学意义的差异（OR:0.57,95%CI:0.31-1.04, P=0.07）。同静脉内给药相比，冠脉内注射GPIs明显增加了TIMI3级血流（OR:1.48,95%CI:1.06-2.06, P=0.02）和TMPG2-3级血流（OR:2.63,95%CI:1.53-4.51, P=0.0004）。中长期MACEs发生率、LVEF和出血并发症在两组之间无明显差异。
结论：急性冠脉综合征患者PCI治疗时，冠脉内直接注射GPIs比静脉注射大大增加靶血管血流量和心肌再灌注，且不增加出血风险，但对临床预后的改善并不优于静脉给药。
Association between Autoantibody againstIC53Gene and Prognosis of Patients with Heart Failure
Background: Heart failure (HF) is the final clinical entity of many diverse diseasecauses and mechanisms. During the last years, it has been discovered that autoimmunity playsan important role in the progression and induction of heart failure. Circulating autoantibodies,some of them being heart-specific, have been critically linked to heart failure. The objectiveof study is to determine whether autoantibody against IC53gene is related to prognosis ofpatients with heart failure.
Methods: The study included588patients with HF caused by coronary artery disease（CAD） and177patients with HF caused by dilated cardiomyopathy (DCM). Based onsynthetic peptides as antigens, enzyme-linked immunosorbent technique was used firstly todetect the antibody against IC53in serum of the patients. The study population was followedup for a median period of4years until December2013. The end points included cardiac deathand sudden cardiac death (SCD). We performed survival analysis in the HF population. HRs(hazard ratios) for time to cardiac death and SCD from baseline were estimated using Coxproportional hazards models. we analysed Kaplan–Meier curves for time to probability ofsurvival using the log rank test according to positive or negative of antibody against IC53inthe patients with DCM.
Results The positve rates of serum for IC53gene were18.6%and24.1%in CHFpatients with DCM and patients with CAD. During a median follow-up period of4years(range,0.4–78months), mortality of patients with DCM was42.9%and mortality ofpatients with CAD was27.1%. Mortality of patients with positive antibody against IC53genein DCM team was60.6%; mortality of patients without positive antibody against IC53gene inDCM team was38.9%. Mortality of patients with positive antibody against IC53gene inCAD team was28.6%; Mortality of patients without positive antibody against IC53gene inCAD team was26.6%. After adjustment for age, gender and suspected risk factors by using asurvival Cox regression analysis, positive antibody against IC53gene in the patients with DCM had an increased risk of cardiac death compared with negative of antibody against IC53in the patients with DCM（P=0.010，HR=1.96,95%CI：1.17-3.28）. Positive antibody againstIC53gene in the patients with CAD had no increased risk of cardiac death compared withnegative of antibody against IC53in the patients with IHD (P=0.933，OR=1.02,95%CI：0.71-1.46).
Conclusion: Our results indicated that autoantibody against IC53gene can be detectedin patients with HF. Autoantibody against IC53gene can increase risk of cardiac death in HFcaused by DCM, and serves as an independent predictor of cardiac death.
A Comparison of Intracoronary with Intravenous GlycoproteinⅡb/Ⅲa Inhibitors during Percutaneous Coronary Intervention in Patientswith Acute Coronary Syndrome：A Meta-analysis of Randomized
Controlled Trials.
Background-It is still debatable whether intracoronary(IC) administration ofglycoprotein IIb/IIIa inhibitors (GPIs) is superior to intravenous (IV) administration forpatients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention(PCI).
Methods-We performed a meta-analysis of randomized controlled clinical trials. Aliterature search was conducted for relevant trials. Primary end points were short-term (1-3months) and mid-/long term (6/12months) major cardiovascular adverse events(MACEs)(mortality, re-infarction, target vessel revascularization). Secondary end points wereThrombolysis In Myocardial Infarction (TIMI) grade flow, TIMI myocardial perfusion grade(TMPG) flow, left ventricular ejection fraction (LVEF) within2weeks, bleedingcomplication.
Results-Twelve studies were included in the meta-analysis. IC administration of GPIsdid not decrease short-term mortality (OR:0.71,95%CI:0.41-1.23, P=0.22) andre-infarction rate (OR:0.76,95%CI:0.45-1.29, P=0.31) compared with IV administration.There was a trend towards reduction of short-term TVR rate in IC group compared with IVgroup but not reached statistical significance (OR:0.57,95%CI:0.31-1.04, P=0.07). ICadministration of GPIs significantly increased TIMI grade3flow (OR:1.48,95%CI:1.06-2.06, P=0.02) and TMPG grade2-3flow (OR:2.63,95%CI:1.53-4.51, P=0.0004)compared with IV administration. No significant difference was observed in long-termMACEs rate, LVEF and bleeding complication between the2groups.
Conclusion-IC administration of GPIs in patients with ACS undergoing PCI cansignificantly increase target coronary flow and myocardial reperfusion without increasing the risk of bleeding complication, but can not improve clinical outcome compared with IVadministration.
引文
[1] WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J,Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, JohnsonMR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE,Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL;Circulation.2013Oct15;128(16):e240-327.
[2] Adams KF, Jr., Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, AbrahamWT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific AdvisoryCommittee and Investigators. Characteristics and outcomes of patients hospitalized forheart failure in the United States: rationale, design, and preliminary observations fromthe first100,000cases in the Acute Decompensated Heart Failure National Registry(ADHERE). Am Heart J.2005;149:209-16.
[3] Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartanin chronic heart failure. N Engl J Med.2001;345:1667-75.
[4] Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC; MERIT-HF StudyGroup. Metoprolol CR/XL in female patients with heart failure: analysis of theexperience in Metoprolol Extended-Release Randomized Intervention Trial in HeartFailure (MERIT-HF). Circulation.2002;105:1585-91.
[5] Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med.1994;331:1564-75.
[6] o AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM,Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA,Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, MohlerER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J,Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart AssociationStatistics Committee and Stroke Statistics Subcommittee.. Heart disease and strokestatistics--2013update: a report from the American Heart Association. Circulation.2013;127:e6-245.
[7]中国心血管病中心，中国心血管病报告，2012.
[8] Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, BravataDM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, HeitJA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, MohlerER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, SteinJ, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart AssociationStatistics Committee and Stroke Statistics Subcommittee. Heart disease and strokestatistics--2013update: a report from the American Heart Association. Circulation.2013;127:e6-245.
[9] Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP,Jacobsen SJ. Trends in heart failure incidence and survival in a community-basedpopulation. JAMA.2004;292:344-50.
[10] Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM,Vasan RS. Long-term trends in the incidence of and survival with heart failure. N EnglJ Med.2002;347:1397-402.
[11] Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, Wang Y,Lin Z, Straube BM, Rapp MT, Normand SL, Drye EE. Patterns of hospitalperformance in acute myocardial infarction and heart failure30-day mortality andreadmission. Circ Cardiovasc Qual Outcomes.2009;2:407-13.
[12] Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD，Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, NicholG, Orenstein D, Wilson PW, Woo YJ. Forecasting the future of cardiovascular diseasein the United States: a policy statement from the American Heart Association.Circulation.2011;123:933-44.
[13] Titler MG, Jensen GA, Dochterman JM, Xie XJ, Kanak M, Reed D, Shever LL. Costof hospital care for older adults with heart failure: medical, pharmaceutical, andnursing costs. Health Serv Res.2008;43:635-55.
[14] Wang G, Zhang Z, Ayala C, Wall HK, Fang J. Costs of heart failure-relatedhospitalizations in patients aged18to64years. Am J Manag Care.2010;16:769-76.
[15] Paradis P; Dali Youcef N; Paradis FW; Thibault G; Nemer M; Overexpression ofangiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy andremodeling. Proc Natl Acad Sci USA.2000V97N2.931-936.
[16] Burniston JG; Saini A; TanLB; Gold spink DF; Aldosterone induces myocyteapoptosis in the heart and skeletal muscles of rats in vivo.J Mol Cell Cardiol.2005V39N2.
[17] Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, AumontMC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y. Plasma brain natriureticpeptide-guided therapy to improve outcome in heart failure: the STARS-BNPMulticenter Study. J Am Coll Cardiol.2007Apr24;49(16):1733-9. Epub2007Apr2.
[18] Stewart JA Jr, Massey EP, Fix C, Zhu J, Goldsmith EC, Carver W. Temporalalterations in cardiac fibroblast function following induction of pressure overload.CellTissue Res.2010Apr;340(1):117-26.
[19] Nishida K,Otsu K.Cell death in heart failure. Circ J.2008;72Suppl A:A17-21.
[20] Chandrashekhar Y;Role of apoptosis in ventricular remodeling.Curr Heart Fail Rep.2005V2N1.18-22
[21] Wu F, Zhang J, Beard DA.Experimentally observed phenomena on cardiac energeticsin heart failure emerge from simulations of cardiac metabolism.Proc Natl Acad Sci USA.2009Apr28;106(17):7143-8.
[22] Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res.2009Feb15;81(3):412-9.
[23] Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression ofangiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy andremodeling.Proc Natl Acad Sci USA.2000Jan18;97(2):931-6.
[24] Horio T. Nihon Rinsho.Pathophysiological role of cytokines in heart failure.2006May;64(5):843-7.
[25] Kao YH, Chen YC, Cheng CC, Lee TI, Chen YJ, Chen SA.Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promotermethylation in cardiomyocytes. Crit Care Med.2010Jan;38(1):217-22.
[26] Bovill E, Westaby S, Reji S, Sayeed R, Crisp A, Shaw T.Induction by left ventricularoverload and left ventricular failure of the human Jumonji gene (JARID2) encoding aprotein that regulates transcription and reexpression of a protective fetal program. JThorac Cardiovasc Surg.2008Sep;136(3):709-16.
[27] Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream ofNFATc3to regulate cardiac hypertrophy. Proc Natl Acad Sci USA.2009Jul21；106(29):12103-8.
[28] Kocksk mper J, Zima AV, Roderick HL, Pieske B, Blatter LA, Bootman MD.Emerging roles of inositol1,4,5-trisphosphate signaling in cardiac myocytes. J MolCell Cardiol.2008Aug;45(2):128-47.
[29] Dent MR, Dhalla NS, Tappia PS. Phospholipase C gene expression, protein content,and activities in cardiac hypertrophy and heart failure due to volume overload. Am JPhysiol Heart Circ Physiol.2004Aug;287(2):H719-27.
[30] Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato Y, Mori Y, Nagao T,Kurose H.TRPC3and TRPC6are essential for angiotensin II-induced cardiachypertrophy. EMBO J.2006Nov15;25(22):5305-16.
[31] Torre-Amone G. Immune activation in chronic heart failure.Am J Cardiol，2005,95(1IA):3C-8C.
[32] Caforio AL，Mahon NJ，Tona F，McKenna WJ. Circulating cardiac autoantibodies indilated in cardiomyopathy and myocarditis: pathogenetic and clinical significance.EurJ Heart Fail，2002,4(4):411-417.
[33] Levin MJ, Hoebeke J. Cross-talk between anti-beta1-adrenoceptor antibodies indilated cardiomyopathy and Chagas' heart disease. Autoimmunity.2008;6:429–433.
[34] Liang CS, Mao W, Liu J. Pro-apoptotic effects of anti-beta1-adrenergic receptorantibodies in cultured rat cardiomyocytes: actions on endoplasmic reticulum and theprosurvival PI3K-Akt pathway. Autoimmunity.2008;6:434–441.
[35] Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complementpathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmicautoantibodies. Am J Pathol.2007;1:52–64.
[36] Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictorsof readmission among elderly survivors of admission with heart failure. Am Heart J.2000;139:72-7.
[37] Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS,Foody JM, Gerber TC, Hinderliter AL, King SB3rd, Kligfield PD, Krumholz HM,Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF,Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV, AndersonJL; American College of Cardiology Foundation/American Heart Associati-on TaskForce.2012ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosisand management of patients with stable ischemic heart disease: a report of theAmerican College of Cardiology Foundation/American Heart Association Task Forceon Practice Guidelines, and the American College of Physicians, AmericanAssociation for Thoracic Surgery, Preventive Cardiovascular Nurses Association,Society for Cardiovascular Angiography and Interventions, and Society of ThoracicSurgeons. Circulation.2012;126:e354-471.
[38] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW,Materson BJ, Oparil S, Wright JT Jr, Roccella EJ.Seventh report of the Joint NationalCommittee on Prevention, Detection, Evaluation, and Treatment of High BloodPressure. Hypertension.2003;42:1206-52.
[39] Standards of medical care in diabetes--2012. Diabetes Care.2012;35Suppl1:S11-S63.
[40] Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, FranklinBA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M,Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA; World HeartFederation and the Preventive Cardiovascular Nurses Association. AHA/ACCFsecondary prevention and risk reduction therapy for patients with coronary and otheratherosclerotic vascular disease:2011update: a guideline from the American HeartAssociation and American College of Cardiology Foundation. Circulation.2011;124:2458-73.
[41] Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression fromhypertension to congestive heart failure. JAMA.1996;275:1557-62.
[42] Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, PerryHM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, CurbJD, Smith WM, McDonald R, Applegate WB.Prevention of heart failure byantihypertensive drug treatment in older persons with isolated systolic hypertension.SHEP Cooperative Research Group. JAMA.1997;278:212-6.
[43] Izzo JL, Jr., Gradman AH. Mechanisms and management of hypertensive heart disease:from left ventricular hypertrophy to heart failure. Med Clin North Am.2004;88:1257-71.
[44] Baker DW. Prevention of heart failure. J Card Fail.2002;8:333-46.
[45] Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D.Residual lifetime risk for developing hypertension in middle-aged women and men:The Framingham Heart Study. JAMA.2002;287:1003-10.
[46] Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart indiabetes: Part I: general concepts. Circulation.2002;105:1727-33.
[47] Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB,Vasan RS. Obesity and the risk of heart failure. N Engl J Med.2002;347:305-13.
[48] He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors forcongestive heart failure in US men and women: NHANES I epidemiologic follow-upstudy. Arch Intern Med.2001;161:996-1002.
[49] Anderson JL, Adams CD, Antman EM, et al. ACC/AHA2007guidelines for themanagement of patients with unstable angina/non ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association task forceon practice guidelines (Writing committee to revise the2002guidelines for themanagement of patients with unstable angina/non ST-elevation myocardial infarction):developed in collaboration with the American College of Emergency Physicians, thesociety for cardiovascular angiography and interventions, and the Society of ThoracicSurgeons: endorsed by the American Association of Cardiovascular and PulmonaryRehabilitation and the Society for Academic Emergency Medicine. Circulation2007;116: e148-304.
[50] Chen J, Liu B, Liu Y, Han Y, Yu H, Zhang Yet al.A novel gene IC53stimulatesECV304cell proliferation and is upregulated in failing heart. Biochem Biophys ResCommun2002;294:161–166.
[51]韩霞,王建春,王曙霞,惠汝太.心肌细胞自身抗体的研究进展.中国分子心脏病学杂志,2005,5(6):813-817.
[52] Gohlke H, Albus C, Gysan DB, Hahmann HW, Mathes P; ESC. Cardiovascularprevention in clinical practice (ESC and German guidelines2007). Herz2009;34:4-14.
[53] Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol1991;68:28B–35B.
[54] Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in suddencardiac ischemic death. N Engl J Med1984;310:1137–1140.
[55] Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, Masuyama T, Kitabatake A,Minamino T. Lack of myocardial perfusion immediately after successful thrombolysis.A predictor of poor recovery of left ventricular function in anterior myocardialinfarction. Circulation1992;85:1699-1705.
[56] van't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of12-leadelectrocardiogram after successful reperfusion therapy for acute myocardial infarction.Zwolle Myocardial Infarction Study Group. Lancet1997;350:615-619.
[57] Iliceto S, Marangelli V, Marchese A, Amico A, Galiuto L, Rizzon P. Myocardialcontrast echocardiography in acute myocardial infarction: pathophysiologicalbackground and clinical application. Eur Heart J1996;17:344-353.
[58] van 't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F.Angiographic assessment of myocardial reperfusion in patients treated with primaryangioplasty for acute myocardial infarction. Myocardial Blush Grade. Circulation1998;97:2302-2306.
[59] Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction:underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol2010;55:1649-1660.
[60] Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am CollCardiol2009;54:281–292.
[61] De Luca G, van 't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH,Zijlstra F, de Boer MJ, Suryapranata H. Unsuccessful reperfusion in patients withST-segment elevation myocardial infarction treated by primary angioplasty. Am HeartJ2005;150:557–562.
[62] Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F. Rationalefor intracoronary administration of abciximab. J ThrombThrombolysis.2007;23:57–63.
[63] Kouz R, Kouz S, Schampaert E, Rinfret S, Tardif JC, Nguyen M, Eisenberg M,Harvey R, Afilalo M, Lauzon C, Dery JP, Mansour S, Huynh T. Effectiveness andsafety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarctionundergoing primary percutaneous coronary intervention: A meta-analysis ofobservational studies. Int J Cardiol2011Dec15;153(3):249-55.
[64] Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis ofclinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonistsfor percutaneous coronary intervention.Can J Cardio2007;23:963-970.
[65] De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Vande Werf F, Antman EM, Topol EJ. Abciximab as adjunctive therapy to reperfusion inacute ST-segment elevation myocardial infarction: a meta-analysis of randomizedtrials. JAMA2005293:1759–1765
[66] Randomised placebo-controlled trial of effect of eptifibatide on complications ofpercutaneous coronary intervention: IMPACT-II. Integrilin to Minimise PlateletAggregation and Coronary Thrombosis-II.Lancet1997;349:1422–1428.
[67] The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade withtirofiban on adverse cardiac events in patients with unstable angina or acutemyocardial infarction undergoing coronary angioplasty. Randomized Efficacy Studyof Tirofiban for Outcomes and REstenosis. Circulation1997;96:1445-1453.
[68] Jahns R, Boivin V, Schwarzbach V, Ertl G, Lohse MJ. Pathological autoantibodies incardiomyopathy. Autoimmunity.2008;6:454–461.
[69] Caforio AL, Mahon NG, Baig MK, Tona F, Murphy RT, Elliott PM, McKenna WJ.Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodiespredict disease development in asymptomatic relatives. Circulation.2007;1:76-83.
[70] Felix SB,Staudt A. Non-specific immunoadsorption in patients with dilatedcardiomyopathy: mechanisms and clinical effects. Int J Cardiol.2006;1:30-33.
[71] Doesch AO, Mueller S, Nelles M, Konstandin M, Celik S, Frankenstein L, Goeser S,Kaya Z, Koch A, Zugck C,Katus HA. Impact of troponin I-autoantibodies in chronicdilated and ischemic cardiomyopathy. Basic Res Cardiol.2011;1:25-35.
[72] Wallukat G. The beta-adrenergic receptors. Herz.2002;7:683–690.
[73] Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors inhuman idiopathic dilated cardiomyopathy. Circ Res.1989;1:97–103.
[74] Magnusson Y, Marullo S, Hoyer S, Waagstein F, Andersson B, Vahlne A, Guillet JG,Strosberg AD, Hjalmarson A, Hoebeke J. Mapping of a functional autoimmuneepitope on the beta1-adrenergic receptor in patients with idiopathic dilatedcardiomyopathy. J Clin Invest.1990;5:1658–1663.
[75] Liu HR, Zhao RR, Jiao XY, Wang YY, Fu M. Relationship of myocardial remodelingto the genesis of serum autoantibodies to cardiac beta(1)-adrenoceptors andmuscarinic type2acetylcholine receptors in rats. J Am Coll Cardiol.2002;11:1866–1873.
[76] Mobini R，Fu M，Wallukat G. A monoclonal anitibody directed against an，autoimmune epitope on the human betal-adrenergic receptor，recognized in iniopathinin dilated cardiomyopathy. Hybridoma，2000，19(2):135-142.
[77] Wallukat G，Wollenberger A，Morwinski R，etal.Anti-beta l-adrenocepter autoanbodieswith chronotropie activity from the serum of patients with dilated cardiomyopathy:mapping of epitopes in the first and second extracellar loops.J Mol cell Cardiol，1995，27(l):397-406.
[78] Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, Takahashi T, OgawaS. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptorsinduces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo.Circ Res.2001;6:578–586.
[79] Jahns R，Boivin V，Siegmund C， Inselmann G, Lohse MJ, Boege F. Autoantibodiesactivating human beta1-adrenergic receptors are associated with reduced cardiacfunction in chronic heart failure. Circulation,1999,99(5):649-654．
[80] Fukuda Y, Miyoshi S, Tanimoto K, Oota K, Fujikura K, Iwata M, Baba A, HagiwaraY, Yoshikawa T, Mitamura H, Ogawa S. Autoimmunity against the second extracellularloop of beta(1)-adrenergic receptors induces early afterdepolarization and decreases inK-channel density in rabbits. J Am Coll Cardiol2004Mar17;43(6):1090-100.
[81] Staudt Y，Mobini R，Fu M，Felix SB, Kühn JP, Staudt A．Beta1-adrenoceptor antibodiesinduce apoptosis in adult isolated cardiomyocytes． Eur J Phar-macol,2003,466(2):1-6．
[82] Deubner N, Berliner D, Schlipp A, Gelbrich G, Caforio AL, Felix SB, Fu M, Katus H,Angermann CE, Lohse MJ, Ertl G, Stork S, Jahns R. Cardiac beta1-adrenoceptorautoantibodies in human heart disease: rationale and design of the Etiology,Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail.2010;7:753–762.
[83] Di LA, Remme WJ, Charlesworth A, Cleland JG, Lutiger B, Metra M, Komajda M,Torp-Pedersen C, Scherhag A, Swedberg K, Poole-Wilson PA. Exchange ofbeta-blockers in heart failure patients. Experiences from the poststudy phase ofCOMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail.2005;4:640–649.
[84] Jahns R, Schlipp A, Boivin V, Lohse MJ. Targeting receptor antibodies in immunecardiomyopathy. Semin Thromb Hemost.2010;2:212–218.
[85] Greenberg B. Nonselective versus selective beta-blockers in the management ofchronic heart failure: clinical implications of the carvedilol or Metoprolol EuropeanTrial. Rev Cardiovasc Med.2004;5: S10–S17.
[86] Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Baba A, Anzai T, Meguro T, SatohT, Ogawa S. A pilot study on the role of autoantibody targeting the beta1-adrenergicreceptor in the response to beta-blocker therapy for congestive heart failure. J CardFail.2009;3:224–232.
[87] Fu ML. Anti-peptide antibodies against an autoimmune epitope on human muscarinicreceptor mimic functional autoantibodies against the same epitope in patients withidiopathic dilated cardiomyopathy. Eur Heart J.1995Dec;16Suppl O:89-91.
[88] Fu LX, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, HoebekeJ. Localization of a functional autoimmune epitope on the muscarinic acetylcholinereceptor-2in patients with idiopathic dilated cardiomyopathy. J Clin Invest.1993;5:1964–1968.
[89] Matsui S, Fu ML, Shimizu M, Fukuoka T, Teraoka K, Takekoshi N, Murakami E,Hjalmarson A. Dilated cardiomyopathy defines serum autoantibodies againstG-protein-coupled cardiovascular receptors. Autoimmunity.1995;2:85–88.
[90] Fu ML, Hoebeke J, Matsui S, Matoba M, Magnusson Y, Hedner T, Herlitz H,Hjalmarson A. Autoantibodies against cardiac G-protein-coupled receptors definedifferent populations with cardiomyopathies but not with hypertension. Clin ImmunolImmunopathol.1994;1:15–20.
[91] Matsui S, Fu ML, Katsuda S, Hayase M, Yamaguchi N, Teraoka K, Kurihara T,Takekoshi N, Murakami E, Hoebeke J, Hjalmarson A. Peptides derived fromcardiovascular G-protein-coupled receptors induce morphological cardiomyopathicchanges in immunized rabbits. J Mol Cell Cardiol.1997;2:641–655.
[92] Hernandez CC，Barcellos LC，Gimenez LE，et al． Human chagasic IgGs bind tocardiac muscarinic receptors and impair L-type Ca2+currents．Cardiovasc Res,2003,58(1):55-65．
[93] Akiyasu B，Tsutom U，Yoshikawa，et al． Autoantibddies against M2-muscarinicacetylcholine receptors: new upstream targets in atrial fibrillationin patients withdilated cardiomyopathy．European Heart Joumal,2004,25(3):1107-1115．
[94] Chiale PA, Ferrari I, Mahler E, Vallazza MA, Elizari MV, Rosenbaum MB, Levin MJ.Differential profile and biochemical effects of antiautonomic membrane receptorantibodies in ventricular arrhythmias and sinus node dysfunction. Circulation2001;103:1765-1771.
[95] Stavrakis S, Kem DC, Patterson E, Lozano P, Huang S, Szabo B, Cunningham MW,Lazzara R, Yu X. Opposing cardiac effects of autoantibody activation ofbeta-adrenergic and M2muscarinic receptors in cardiac-related diseases. Int J Cardiol.2011;3:331–336.
[96] Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S,Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy inPD-1receptor-deficient mice. Science.2001;5502:319–322.
[97] Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H,Matsumori A, Minato N, Honjo T. Autoantibodies against cardiac troponin I areresponsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med.2003;12:1477–1483.
[98] Goser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Ottl R, Zittrich S, Blaudeck N,Hardt SE, Pfitzer G, Rose NR, Katus HA, Kaya Z. Cardiac troponin I but not cardiactroponin T induces severe autoimmune inflammation in the myocardium. Circulation.2006;16:1693–1702.
[99] Kaya Z, Goser S, Buss SJ, Leuschner F, Ottl R, Li J, Volkers M, Zittrich S, Pfitzer G,Rose NR, Katus HA. Identification of cardiac troponin I sequence motifs leading toheart failure by induction of myocardial inflammation and fibrosis. Circulation.2008;20:2063–2072.
[100] Leuschner F, Li J, Goser S, Reinhardt L, Ottl R, Bride P, Zehelein J, Pfitzer G,Remppis A, Giannitsis E, Katus HA, Kaya Z. Absence of auto-antibodies againstcardiac troponin I predicts improvement of left ventricular function after acutemyocardial infarction. Eur Heart J.2008;16:1949–1955.
[101] Miettinen KH, Eriksson S, Magga J, Tuomainen P, Kuusisto J, Vanninen EJ, TurpeinenA, Punnonen KR, Pettersson K, Peuhkurinen KJ. Clinical significance of troponin Iefflux and troponin autoantibodies in patients with dilated cardiomyopathy. J Card Fail.2008;6:481–488.
[102] Mercadier JJ, Bouveret P, Gorza L, Schiaffino S, Clark WA, Zak R, Swynghedauw B,Schwartz K. Myosin iso enzymes in normal and hypertrophied human ventricularmyocardium. Circ Res.1983;1:52–62.
[103] Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiacmyosin induces myocarditis in genetically predisposed mice. J Immunol.1987;11:3630–3636.
[104] Neumann DA, Rose NR, Ansari AA, Herskowitz A. Induction of multiple heartautoantibodies in mice with coxsackievirus B3-and cardiac myosin-inducedautoimmune myocarditis. J Immunol.1994;1:343–350.
[105] Lauer B, Padberg K, Schultheiss HP, Strauer BE. Autoantibodies against humanventricular myosin in sera of patients with acute and chronic myocarditis. J Am CollCardiol.1994;1:146–153.
[106] Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ,Schiaffino S. Identification of alpha-and beta-cardiac myosin heavy chain isoforms asmajor autoantigens in dilated cardiomyopathy. Circulation.1992;5:1734–1742.
[107] Lauer B, Schultheiss HP, Padberg K. Autoantibodies against cardiac myosin inpatients with myocarditis and dilated cadriomyopathy. Z Kardio,1995,84(4):301-310.
[108] Kuan AP, Chamberlain W, Malkiel S, Lieu HD, Factor SM, Diamond B, Kotzin B.Genetic control of autoimmune myocarditis mediated by myosin-specific antibodies.Immunogenetics.1999;2:79–85.
[109] Kuan AP, Zuckier L, Liao L, Factor SM, Diamond B. Immunoglobulin isotypedetermines pathogenicity in antibody-mediated myocarditis in naive mice. Circ Res.2000;3:281–285.
[110] Warraich RS, Noutsias M, Kazak I, Seeberg B, Dunn MJ, Schultheiss HP, Yacoub MH,Kuhl U. Immunoglobulin G3cardiac myosin autoantibodies correlate with leftventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3and clinical correlates. Am Heart J.2002;6:1076–1084.
[111] Warraich RS, Griffiths E, Falconar A, Pabbathi V, Bell C, Angelini G, Suleiman MS,Yacoub MH. Human cardiac myosin autoantibodies impair myocyte contractility: acause-and-effect relationship. FASEB J.2006;6:651–660.
[112] Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry andantibody-mediated cell signaling in autoimmune myocarditis. J Immunol.2006;11:8234–8240.
[113] Saito S, Hiroi Y, Zou Y, Aikawa R, Toko H, Shibasaki F, Yazaki Y, Nagai R, Komuro I.beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiacmyocytes. J Biol Chem.2000;44:34528–34533.
[114] Lv H, Havari E, Pinto S, Gottumukkala RV, Cornivelli L, Raddassi K, Matsui T,Rosenzweig A, Bronson RT, Smith R, Fletcher AL, Turley SJ, Wucherpfennig K,Kyewski B, Lipes MA. Impaired thymic tolerance to alpha-myosin directsautoimmunity to the heart in mice and humans. J Clin Invest.2011;4:1561–1573.
[115] Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in thethymus for positive selection and central tolerance induction. Nat Rev Immunol.2009;12:833–844.
[116] Berg PA, Klein R. Mitochondrial antigens and autoantibodies: from anti-M1toanti-M9. Klin Wochenschr.1986;19:897–909.
[117] Klein R, Maisch B, Kochsiek K, Berg PA. Demonstration of organ specific antibodiesagainst heart mitochondria (anti-M7) in sera from patients with some forms of heartdiseases. Clin Exp Immunol.1984;2:283–292.
[118] Bottazzo GF, Todd I, Mirakian R, Belfiore A, Pujol-Borrell R. Organ-specificautoimmunity: a1986overview. Immunol Rev.1986;94:137–169.
[119] Schultheiss HP, Schwimmbeck P, Bolte HD, Klingenberg M. The antigeniccharacteristics and the significance of the adenine nucleotide translocator as a majorautoantigen to antimitochondrial antibodies in dilated cardiomyopathy. AdvMyocardiol.1985;6:311-327.
[120] Kuhl U, Melzner B，Schafer B, etal.The Ca-channel as cardiac autoantigen. Eur HeartJ,1991,12suppl D:99-104.
[121] Schultheiss HP, Bolte HD. Immunological analysis of auto-antibodies against theadenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol.1985;17:603–617.
[122] Maack C, O’ Rourke B. Excitation-contraction coupling and mitochondrial energetics.Basic Res Cardiol,2007,102(5):369-392.
[123] Schulze K, Witzenbichler B, Christmann C, Schultheiss HP. Disturbance ofmyocardial energy metabolism in experimental virus myocarditis by antibodies againstthe adenine nucleotide translocator. Cardiovasc Res.1999;1:91–100.
[124] Liao YH，Yuan J，Wang ZH，Cheng X, Zhang JH, Tian Y, Dong JH, Guo HP, Wang M.Infectious tolerance to ADP/ATP carrier peptides induced by anti-L3T4monoclonalantibody indilated cardiomyopathy mice. J Clin Immuno，2005，25(4):376-384.
[125] Mobini R, Maschke H, Waagstein F.New insights into the pathogenesis of dilatedcardiomyopathy: possible underlying autoimmune mechanisms and therapy.Autoimmun Rev.2004Jun;3(4):277-84.
[126] Manchado C, Orus J, Villarroya F, Roig E, Heras M, Giralt M, Iglesias R, Sanz G,Mampel T, Vinas O. Epitope mapping of mitochondrial adenine nucleotide translocase-1in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol.2002;5:571–582.
[127] Andreoletti L, Leveque N, Boulagnon C, Brasselet C, Fornes P. Viral causes ofhuman myocarditis. Arch Cardiovasc Dis.2009;6–7:559–568.
[128] Schulze K, Heineman FW, Schultheiss HP, Balaban RS. Impairment of myocardialcalcium homeostasis by antibodies against the adenine nucleotide translocator. CellCalcium.1999;5:361–370.
[129] Michels VV，Moll PP，Rodeheffer RJ et al.Circulating heart autoantibodies in familialas compared with nofamilial idiopathic dilated cardiomyopathy. Mayo Clin Proc,1994,69(1):24-27.
[130] Takemoto M，Kusachi S, Urabe N, Inoue K, Tsuji T. Auto-antibody against adeninenucleotide translocator in dilated cardiomyopathy and myocarditis-incidence andrelation to cardiac function and morphology. Jpn Circ J,1993,57(12):1150-1158.
[131] Norgaard A, Bagger JP, Bjerregaard P, Baandrup U, Kjeldsen K, Thomsen PE.Relation of left ventricular function and Na,K-pump concentration in suspectedidiopathic dilated cardiomyopathy. Am J Cardiol.1988;15:1312–1315.
[132] Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmalNa-K-ATPase: possible upstream targets of arrhythmias and sudden death in patientswith dilated cardiomyopathy. J Am Coll Cardiol.2002;6:1153–1159.
[133] Baba A, Yoshikawa T, Iwata M, Anzai T, Nakamura I, Wainai Y, Ogawa S, Fu M.Antigen-specific effects of autoantibodies against sarcolemmal Na-K-ATPase pump inimmunized cardiomyopathic rabbits. Int J Cardiol.2006;1:15–20.
[134] Winrow VR, McLean L, Morris CJ, Blake DR. The heat shock protein response andits role in inflammatory disease. Ann Rheum Dis.1990;2:128–132.
[135] Latif N, Smith J, Dunn MJ, Yacoub MH, Rose ML. Complement-mediated cytotoxicactivity of anti-heart antibodies present in the sera of patients with dilatedcardiomyopathy. Autoimmunity.1994;2:99–104.
[136] Lin L, Kim SC, Wang Y, Gupta S, Davis B, Simon SI, Torre-Amione G, Knowlton AA.HSP60in heart failure: abnormal distribution and role in cardiac myocyte apoptosis.Am J Physiol Heart Circ Physiol.2007;4: H2238–H2247.
[137] Ching YP, Qi Z, Wang JH. Cloning of three novel neuronal Cdk5activator bindingproteins.Gene2000;242:285–294.
[138]陈敬洲,韩玉,张银辉,等. IC53基因超表达改变系列心衰相关基因表达水平.中国分子心胜病学杂志,2005,5(1):401-404.
[139] Bkaily G, El-Bizri N, Bui M, Sukarieh R, Jacques D, Fu ML.Modulation ofintracellular Ca2+via L-type calcium channels in heart cells by the autoantibodydirected against the second extracellular loop of the alpha1-adrenoceptors. Can JPhysiol Pharmacol.2003Mar;81(3):234-246.
[140]陈敬洲,韩玉,张银辉,等. IC53基因在血管及动脉粥样硬化斑块中的表达谱分析.中国分子心胜病学杂志,2005,5(3):523-524.
[141]韩霞,亓维东,陈敬洲,惠汝太,张志强,张增堂.心力衰竭患者中IC53基因自身抗体的研究.临床心血管病杂志2011,27(4):263-267.
[142] Wallukat G, Reinke P, Dorffel WV, Luther HP, Bestvater K, Felix SB, Baumann G.Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int JCardiol.1996;2:191-195.
[143] Cooper LT, Belohlavek M,Korinek J,Yoshifuku S, Sengupta PP, Burgstaler EA,Winters JL. A pilot study to assess the use of protein a immunoadsorption for chronicdilated cardiomyopathy. J Clin Apher.2007;4:210-214.
[144] Knebel F, Bohm M, Staudt A, Borges AC, Tepper M, Jochmann N, Wernicke KD,Felix S, Baumann G. Reduction of morbidity by immunoadsorption therapy in patientswith dilated cardiomyopathy. Int J Cardiol.2004;3:517-520.
[145] Staudt A, Hummel A, Ruppert J, Dorr M, Trimpert C, Birkenmeier K, Krieg T, StaudtY, Felix SB. Immunoadsorption in dilated cardiomyopathy:6-month results from arandomized study. Am Heart J.2006;4:712-716.
[146] Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S,Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G. Hemodynamiceffects of immunoadsorption and subsequent immunoglobulin substitution in dilatedcardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol.2000;6:1590-1598.
[147] Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K, Wallukat G,Wernecke KD, Stangl K, Baumann G, Felix SB Immunohistological changes in dilatedcardiomyopathy induced by immunoadsorption therapy and subsequentimmunoglobulin substitution. Circulation.2001;22:2681-2686.
[148] Anderson JL, Carlquist JF, Lutz JR, DeWitt CW, Hammond EH. HLA A, B and DRtyping in idiopathic dilated cardiomyopathy: a search for immune response factors.Am J Cardiol.1984;9:1326-1330.
[149] Harcombe AA, Sharples L, Large SR, Wallwork J, Weissberg PL, Joysey V. HLAantigen frequencies in end-stage idiopathic and ischaemic cardiomyopathy. Int JCardiol.1999;1::31-37.
[150] Kallwellis-Opara A, Staudt A, Trimpert C, Noutsias M, Kuhl U, Pauschinger M,Schultheiss HP, Grube M, Bohm M, Baumann G, Volker U, Kroemer HK, Felix SB.Immunoadsorption and subsequent immunoglobulin substitution decreases myocardialgene expression of desmin in dilated cardiomyopathy. J Mol Med.2007;12:1429–1435.
[151] Orozco AF, Lewis DE. Flow cytometric analysis of circulating microparticles inplasma. Cytometry A.2010;6:502–514.
[152] Nozaki T, Sugiyama S, Sugamura K, Ohba K, Matsuzawa Y, Konishi M, Matsubara J,Akiyama E, Sumida H, Matsui K, Jinnouchi H, Ogawa H. Prognostic value ofendothelial microparticles in patients with heart failure. Eur J Heart Fail.2010;11:1223–1228.
[153] Bulut D, Scheeler M, Niedballa LM, Miebach T, Mugge A. Effects ofimmunoadsorption on endothelial function, circulating endothelial progenitor cells andcirculating microparticles in patients with inflammatory dilated cardiomyopathy. ClinRes Cardiol.2011;100:603–610.
[154] Mobini R, Staudt A, Felix SB, Baumann G, Wallukat G, Deinum J, Svensson H,Hjalmarson A, Fu M. Hemodynamic improvement and removal of autoantibodiesagainst beta1-adrenergic receptor by immunoadsorption therapy in dilatedcardiomyopathy. J Autoimmun.2003;4:345–350.
[155] Torre-Amione G, Sestier F, Radovancevic B, Young J. Broad modulation of tissueresponses (immune activation) by celacade may favorably influence pathologicprocesses associated with heart failure progression. Am J Cardiol.2005Jun6;95(11A):30C-37C.
[156] Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P,Keren A, Motro M, Moyé LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleau JL,Sestier F, Winkelmann BR, Young JB; Advanced Chronic Heart Failure ClinicalAssessment of Immune Modulation Therapy InvestigatorsResults of a non-specificimmunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet.2008Jan19;371(9608):228-36..
[157] Tepliakov AT, Bolotskaia LA, Stepacheva TA, Karaman NV, Rybal'chenko EV, ShilovSN, Maslov AP. Kardiologiia. Suppressive effect of recombinant immunomodulatorronkoleukin on the blood level of antiinflammatory cytokines, anticardiolipinautoantibodies and heart failure.2008;48(8):34-40.
[158] Aukrust P, Yndestad A, Ueland T, Damas JK, Froland SS, Gullestad L. The role ofintravenous immunoglobulin in the treatment of chronic heart failure. Int J Cardiol.2006;1:40–45.
[159] Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S,Kjekshus J, Nitter-Hauge S,Ueland T, Lien E, Froland SS, Aukrust P.Immunomodulating therapy with intravenous immunoglobulin in patients with chronicheart failure. Circulation.2001;2:220–225.
[160] Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection:evolutionary and therapeutic implications. Nat Rev Immunol.2010;5:328–343.
[161] Larsson L, Mobini R, Aukrust P, Gullestad L, Wallukat G, Waagstein F, Fu M.Beneficial effect on cardiac function by intravenous immunoglobulin treatment inpatients with dilated cardiomyopathy is not due to neutralization of anti-receptorautoantibody. Autoimmunity.2004;6–7:489–493.
[162] Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Baba A, Anzai T, Meguro T, SatohT, Ogawa S. A pilot study on the role of autoantibody targeting the beta1-adrenergicreceptor in the response to beta-blocker therapy for congestive heart failure. J CardFail.2009Apr;15(3):224-32.
[163] Chen J, Hu DY, Zhang L, Liu XL, Wu YF, Li J. The effect of carvedilol on cardiacfunction and autoantibodies against the cardiac receptors. Zhonghua Xin Xue GuanBing Za Zhi.2005Jun;33(6):498-501.
[164] Miao GB, Liu JC, Liu MB, Wu JL, Zhang G, Chang J, Zhang L. Autoantibody againstbeta1-adrenergic receptor and left ventricular remodeling changes in response tometoprolol treatment. Eur J Clin Invest.2006Sep;36(9):614-20.
[165] Lippi G, Montagnana M, Danese E, Favaloro EJ, Franchini M. Glycoprotein IIb/IIIainhibitors: an update on the mechanism of action and use of functional testing methodsto assess antiplatelet efficacy. Biomark Med2011;5:63-70.
[166] Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, JordanRE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab:Dispersal of newly formed platelet aggregates. Thromb Haemost2002;87:1020–1025.
[167] Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria C. Disaggregation ofinvitro preformed platelet-rich clots by abciximab increases fibrin exposure andpromotes fibrinolysis. Arterioscler Thromb Vasc Biol2001;21:142–148.
[168] Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared tointravenous abciximab in patients with acute coronary syndromes undergoing percutaneouscoronary intervention: a systematic review and meta-analysis. J Invasive Cardiol2010;22:278-282.
[169] Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality ofreports of meta-analyses of randomised controlled trials: the QUOROM statement.Quality of Reporting of Meta-analyses. Lancet1999;354:1896–1900.
[170] Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Doesquality of reports of randomized trials affect estimates of intervention efficacyreportedin meta-analyses? Lancet1998;352:609–613.
[171] Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials1986;7:177–88.
[172] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ2003;327:557–560.
[173] Bertrand OF, Rodés-Cabau J, Larose E, Nguyen CM, Déry JP, Proulx G, Roy L, PoirierP, Costerousse O, De Larochellière R. Effects of intracoronary compared to intravenousabciximab administration in patients undergoing transradial percutaneous coronaryintervention: A sub-analysis of the EASY trial. Int J Cardio2009;136:165-170.
[174] Kakkar AK, Moustapha A, Hanley HG, Weiss M, Caldito G, Misra P, Reddy PC, Tandon N.Comparison of intracoronary vs. intravenous administration of abciximab in coronarystenting. Catheterization and Cardiovascular Interventions2004;61:31-34.
[175] Erdim R, Erciyes D, G rmez S, Karabay KO, Catako lu AB, Aytekin V, Demiro lu C, GülbaranM. Comparison of intracoronary versus intravenous administration of tirofiban inprimary percutaneous coronary intervention. Anadolu Kardiyol Derg2010;10:340-345.
[176] W hrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, Hombach V, H her M.Reduction of major adverse cardiac events with intracoronary compared withintravenous bolus application of abciximab in patients with acute myocardialinfarction or unstable angina undergoing coronary angioplasty. Circulation2003;107:1840-1843.
[177] Lee CH, Ngo HM, Sewianto A, et al. Comparison between fixed-dose, intracoronarybolus-only versus standard weight-adjusted dose, intravenous bolus and infusionadministration of abciximab in patients undergoing primary percutaneous coronaryintervention. Int J Cardion2010;145:355-357.
[178] Romagnoli E, Burzotta F, Trani C, Mazzari MA, Biondi-Zoccai GG, De Vita M, GiannicoF, Niccoli G, Prati F, Rebuzzi AG, Mongiardo R, Crea F. Angiographic evaluation of theeffect of intracoronary abciximab administration in patients undergoing urgent PCI.Int J Cardiol2005;105:250-255.
[179] K rma C, Erkol A, Pala S, Oduncu V, Dündar C, zgi A, Tigen K, Gibson CM. Intracoronarybolus-only compared with intravenous bolus plus infusion of tirofiban application inpatients with ST-elevation myocardial infarction undergoing primary percutaneouscoronary intervention. Catheter Cardiovasc Interv2011.
[180] Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronaryeptifibatide bolus administration during percutaneous coronary revascularization foracute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptoroccupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.Circulation2010;121:784-791.
[181] Wu TG, Zhao Q, Huang WG, Wei JR, Chen SW, Zhao J, Huang LP, Wang LX. Effect ofIntracoronary Tirofiban in Patients Undergoing Percutaneous Coronary Interventionfor Acute Coronary Syndrome. Circ J2008;72:1605–1609.
[182] Yang XC, Zhang DP, Wang LF, Xu L, Ge YG, Wang HS, Li WM, Ni ZH, Xia K, Lian Y, XueYL, Ma LX. Effects of intracoronary or intravenous tirofiban administration in patientswith acute ST-elevation myocardial infarction undergoing primary percutaneouscoronary intervention. Zhong hua Xin Xue Guan Bing Za Zhi2007Jun;35:517-522.
[183] Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, PedersenS, Jensen KS, Jensen JS. Intracoronary compared to intravenous bolus abciximab duringprimary percutaneous coronary intervention in ST-segment elevation myocardialinfarction (STEMI) patients reduces30-day mortality and target vesselrevascularization: A randomized trial. J Interv Cardiol2011;24:105-111.
[184] Gu YL, Kampinga MA, Wieringa WG, et al. Hansen PR, Galatius S, Madsen JK, EngstroemT, Pedersen S, Jensen KS, Jensen JS.
[185] Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A,M bius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolusabciximab application in patients with ST-elevation myocardial infarction undergoingprimary percutaneous coronary intervention. The randomized leipzig immediatepercutaneous coronary intervention abciximab IV versus IC in ST-elevationmyocardial infarction trial. Circulation2008;118;49-57.
[186] Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Gaudreault V, Proulx G, Barbeau G, DéryJP, Gleeton O, Manh-Nguyen C, No l B, Roy L, Costerousse O,De Larochellière R; EArlyDischarge after Transradial Stenting of CoronarY Arteries in Acute MyocardialInfarction (EASY-MI) Study Investigators. Intracoronary compared to intravenousabciximab and high-dose bolus compared to standard dose in patients withST-segment elevation myocardial infarction undergoing transradial primarypercutaneous coronary intervention: a two-by-two factorial placebo-controlledrandomized study. Am J Cardio2010;105:1520-1527.
[187] Thiele H, W hrle J, Neuhaus P, et al. Intracoronary compared with intravenous bolusabciximab application during primary percutaneous coronary intervention: AIDASTEMI trial.2011Late-Breaking Clinical Trial/Clinical Science: Special ReportsAbstracts. Circulation2011;124:2365-2374.
[188] Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P, Bosa-Ojeda F, Samimi-Fard S,Marrero-Rodriguez F, Kaski JC. Intracoronary versus intravenous abciximabadministration in patients with ST-elevation myocardial infarction undergoingthrombus aspiration during primary percutaneous coronary intervention-Effects onsoluble CD40ligand concentrations. Atherosclerosis2009;206:523-527.
[189] Eitel I, Friedenberger J, Fuernau G, Dumjahn A, Desch S, Schuler G, Thiele H. Intracoronaryversus intravenous bolus abciximab application in patients with ST-elevationmyocardial infarction undergoing primary percutaneous coronary intervention:6-month effects on infarct size and left ventricular function. Clin Res Cardiol2011;100:425-32.
[190] Galache Osuna JG, Sánchez-Rubio J, Calvo I, Diarte JA, Lukic A, Placer LJ. Doesintracoronary abciximab improve the outcome of percutaneous coronary interventions?A randomized controlled trial. Rev Esp Cardiol2006;59:567-74.
[191] Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP. Increase of myocardial salvageand left ventricular function recovery with intracoronary abciximab downstream of thecoronary occlusion in patients with acute myocardial infarction treated with primarycoronary intervention. Catheter Cardiovasc Interv2004;62:186-192.
[192] Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoproteinIIb/IIIa inhibitors. J Interv Cardiol2002;15:45–60.
[193] Moser M, Bertram U, Peter K, Bode C, Ruef J. Abciximab, eptifibatide, and tirofibanexhibit dose-dependent potencies to dissolve platelet aggregates. J CardiovascPharmacol.2003;41:586–592.
[194] Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GB.A monoclonal antibody againstthe platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation andthrombosis in a canine model of coronary angioplasty. Circulation1991;84:2463–2469.
[195] Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo plateletthrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIareceptor: correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation1989;80:1766–1774.
[196] Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE,Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: dispersal ofnewly formed platelet aggregates. Thromb Haemost2002;87:1020-1025.
[197] Kumar A, Herrmann HC. Tirofiban: an investigational platelet glycoprotein IIb/IIIareceptor antagonist. Expert Opin Investig Drugs1997;6:1257-1267.
[198] Hansen RJ, Balthasar JP. Pharmacokinetics, pharmacodynamics, and platelet bindingof an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative ratmodel of immune thrombocytopenic purpura. J Pharmacol Exp Ther2001;298:165-171.
[199] Scarborough RM. Development of eptifibatide. Am Heart J1999;138:1093-104.
[200] Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, WeismanHF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrinanti-platelet antibody Fab7E3in high risk coronary angioplasty. Circulation1994;90:1757–1764.
[201] Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE.Pharmacodynamic profile of short-term abciximab treatment demonstrates prolongedplatelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade.Circulation1998;97:1680–1688.
[202] Topol EJ, Byzova T, Plow EF. Of platelets, integrin αIIbβ3and GPIIb–IIIa blockers:past, present and future perspectives. Lancet1999;353:227–231.
[203] Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER. A comparison ofabciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoingprimary percutaneous coronary intervention. A meta-analysis of contemporaryrandomized controlled trials. Circ Cardiovasc Interv2009;2:230-236.
[204] Amborse JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographicevalution of coronary artery morphology in unstable angina. J Am Coll Cardiol7:472-78,1986.
[205] Falk E. Morphologic features of unstable atherothrombotic plaques underlying acutecoronary syndromes. Am J Cardiol63:114E-120E,1989.
[206] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary arterydisease and the acute coronary syndromes. N Engl J Med326:242-250,1992.
[207] Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, NakamuraH, Ambrose JA. Angioscopic evaluation of coronary syndromes. N Engl J Med326:287-291,1992.
[2] Adams KF, Jr., Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, AbrahamWT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific AdvisoryCommittee and Investigators. Characteristics and outcomes of patients hospitalized forheart failure in the United States: rationale, design, and preliminary observations fromthe first100,000cases in the Acute Decompensated Heart Failure National Registry(ADHERE). Am Heart J.2005;149:209-16.
[3] Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartanin chronic heart failure. N Engl J Med.2001;345:1667-75.
[4] Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC; MERIT-HF StudyGroup. Metoprolol CR/XL in female patients with heart failure: analysis of theexperience in Metoprolol Extended-Release Randomized Intervention Trial in HeartFailure (MERIT-HF). Circulation.2002;105:1585-91.
[5] Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med.1994;331:1564-75.
[6] o AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM,Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA,Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, MohlerER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J,Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart AssociationStatistics Committee and Stroke Statistics Subcommittee.. Heart disease and strokestatistics--2013update: a report from the American Heart Association. Circulation.2013;127:e6-245.
[7]中国心血管病中心，中国心血管病报告，2012.
[8] Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, BravataDM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, HeitJA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, MohlerER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, SteinJ, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart AssociationStatistics Committee and Stroke Statistics Subcommittee. Heart disease and strokestatistics--2013update: a report from the American Heart Association. Circulation.2013;127:e6-245.
[9] Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP,Jacobsen SJ. Trends in heart failure incidence and survival in a community-basedpopulation. JAMA.2004;292:344-50.
[10] Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM,Vasan RS. Long-term trends in the incidence of and survival with heart failure. N EnglJ Med.2002;347:1397-402.
[11] Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, Wang Y,Lin Z, Straube BM, Rapp MT, Normand SL, Drye EE. Patterns of hospitalperformance in acute myocardial infarction and heart failure30-day mortality andreadmission. Circ Cardiovasc Qual Outcomes.2009;2:407-13.
[12] Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD，Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, NicholG, Orenstein D, Wilson PW, Woo YJ. Forecasting the future of cardiovascular diseasein the United States: a policy statement from the American Heart Association.Circulation.2011;123:933-44.
[13] Titler MG, Jensen GA, Dochterman JM, Xie XJ, Kanak M, Reed D, Shever LL. Costof hospital care for older adults with heart failure: medical, pharmaceutical, andnursing costs. Health Serv Res.2008;43:635-55.
[14] Wang G, Zhang Z, Ayala C, Wall HK, Fang J. Costs of heart failure-relatedhospitalizations in patients aged18to64years. Am J Manag Care.2010;16:769-76.
[15] Paradis P; Dali Youcef N; Paradis FW; Thibault G; Nemer M; Overexpression ofangiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy andremodeling. Proc Natl Acad Sci USA.2000V97N2.931-936.
[16] Burniston JG; Saini A; TanLB; Gold spink DF; Aldosterone induces myocyteapoptosis in the heart and skeletal muscles of rats in vivo.J Mol Cell Cardiol.2005V39N2.
[17] Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, AumontMC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y. Plasma brain natriureticpeptide-guided therapy to improve outcome in heart failure: the STARS-BNPMulticenter Study. J Am Coll Cardiol.2007Apr24;49(16):1733-9. Epub2007Apr2.
[18] Stewart JA Jr, Massey EP, Fix C, Zhu J, Goldsmith EC, Carver W. Temporalalterations in cardiac fibroblast function following induction of pressure overload.CellTissue Res.2010Apr;340(1):117-26.
[19] Nishida K,Otsu K.Cell death in heart failure. Circ J.2008;72Suppl A:A17-21.
[20] Chandrashekhar Y;Role of apoptosis in ventricular remodeling.Curr Heart Fail Rep.2005V2N1.18-22
[21] Wu F, Zhang J, Beard DA.Experimentally observed phenomena on cardiac energeticsin heart failure emerge from simulations of cardiac metabolism.Proc Natl Acad Sci USA.2009Apr28;106(17):7143-8.
[22] Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res.2009Feb15;81(3):412-9.
[23] Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression ofangiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy andremodeling.Proc Natl Acad Sci USA.2000Jan18;97(2):931-6.
[24] Horio T. Nihon Rinsho.Pathophysiological role of cytokines in heart failure.2006May;64(5):843-7.
[25] Kao YH, Chen YC, Cheng CC, Lee TI, Chen YJ, Chen SA.Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promotermethylation in cardiomyocytes. Crit Care Med.2010Jan;38(1):217-22.
[26] Bovill E, Westaby S, Reji S, Sayeed R, Crisp A, Shaw T.Induction by left ventricularoverload and left ventricular failure of the human Jumonji gene (JARID2) encoding aprotein that regulates transcription and reexpression of a protective fetal program. JThorac Cardiovasc Surg.2008Sep;136(3):709-16.
[27] Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream ofNFATc3to regulate cardiac hypertrophy. Proc Natl Acad Sci USA.2009Jul21；106(29):12103-8.
[28] Kocksk mper J, Zima AV, Roderick HL, Pieske B, Blatter LA, Bootman MD.Emerging roles of inositol1,4,5-trisphosphate signaling in cardiac myocytes. J MolCell Cardiol.2008Aug;45(2):128-47.
[29] Dent MR, Dhalla NS, Tappia PS. Phospholipase C gene expression, protein content,and activities in cardiac hypertrophy and heart failure due to volume overload. Am JPhysiol Heart Circ Physiol.2004Aug;287(2):H719-27.
[30] Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato Y, Mori Y, Nagao T,Kurose H.TRPC3and TRPC6are essential for angiotensin II-induced cardiachypertrophy. EMBO J.2006Nov15;25(22):5305-16.
[31] Torre-Amone G. Immune activation in chronic heart failure.Am J Cardiol，2005,95(1IA):3C-8C.
[32] Caforio AL，Mahon NJ，Tona F，McKenna WJ. Circulating cardiac autoantibodies indilated in cardiomyopathy and myocarditis: pathogenetic and clinical significance.EurJ Heart Fail，2002,4(4):411-417.
[33] Levin MJ, Hoebeke J. Cross-talk between anti-beta1-adrenoceptor antibodies indilated cardiomyopathy and Chagas' heart disease. Autoimmunity.2008;6:429–433.
[34] Liang CS, Mao W, Liu J. Pro-apoptotic effects of anti-beta1-adrenergic receptorantibodies in cultured rat cardiomyocytes: actions on endoplasmic reticulum and theprosurvival PI3K-Akt pathway. Autoimmunity.2008;6:434–441.
[35] Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complementpathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmicautoantibodies. Am J Pathol.2007;1:52–64.
[36] Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictorsof readmission among elderly survivors of admission with heart failure. Am Heart J.2000;139:72-7.
[37] Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS,Foody JM, Gerber TC, Hinderliter AL, King SB3rd, Kligfield PD, Krumholz HM,Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF,Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV, AndersonJL; American College of Cardiology Foundation/American Heart Associati-on TaskForce.2012ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosisand management of patients with stable ischemic heart disease: a report of theAmerican College of Cardiology Foundation/American Heart Association Task Forceon Practice Guidelines, and the American College of Physicians, AmericanAssociation for Thoracic Surgery, Preventive Cardiovascular Nurses Association,Society for Cardiovascular Angiography and Interventions, and Society of ThoracicSurgeons. Circulation.2012;126:e354-471.
[38] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW,Materson BJ, Oparil S, Wright JT Jr, Roccella EJ.Seventh report of the Joint NationalCommittee on Prevention, Detection, Evaluation, and Treatment of High BloodPressure. Hypertension.2003;42:1206-52.
[39] Standards of medical care in diabetes--2012. Diabetes Care.2012;35Suppl1:S11-S63.
[40] Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, FranklinBA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M,Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA; World HeartFederation and the Preventive Cardiovascular Nurses Association. AHA/ACCFsecondary prevention and risk reduction therapy for patients with coronary and otheratherosclerotic vascular disease:2011update: a guideline from the American HeartAssociation and American College of Cardiology Foundation. Circulation.2011;124:2458-73.
[41] Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression fromhypertension to congestive heart failure. JAMA.1996;275:1557-62.
[42] Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, PerryHM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, CurbJD, Smith WM, McDonald R, Applegate WB.Prevention of heart failure byantihypertensive drug treatment in older persons with isolated systolic hypertension.SHEP Cooperative Research Group. JAMA.1997;278:212-6.
[43] Izzo JL, Jr., Gradman AH. Mechanisms and management of hypertensive heart disease:from left ventricular hypertrophy to heart failure. Med Clin North Am.2004;88:1257-71.
[44] Baker DW. Prevention of heart failure. J Card Fail.2002;8:333-46.
[45] Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D.Residual lifetime risk for developing hypertension in middle-aged women and men:The Framingham Heart Study. JAMA.2002;287:1003-10.
[46] Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart indiabetes: Part I: general concepts. Circulation.2002;105:1727-33.
[47] Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB,Vasan RS. Obesity and the risk of heart failure. N Engl J Med.2002;347:305-13.
[48] He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors forcongestive heart failure in US men and women: NHANES I epidemiologic follow-upstudy. Arch Intern Med.2001;161:996-1002.
[49] Anderson JL, Adams CD, Antman EM, et al. ACC/AHA2007guidelines for themanagement of patients with unstable angina/non ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association task forceon practice guidelines (Writing committee to revise the2002guidelines for themanagement of patients with unstable angina/non ST-elevation myocardial infarction):developed in collaboration with the American College of Emergency Physicians, thesociety for cardiovascular angiography and interventions, and the Society of ThoracicSurgeons: endorsed by the American Association of Cardiovascular and PulmonaryRehabilitation and the Society for Academic Emergency Medicine. Circulation2007;116: e148-304.
[50] Chen J, Liu B, Liu Y, Han Y, Yu H, Zhang Yet al.A novel gene IC53stimulatesECV304cell proliferation and is upregulated in failing heart. Biochem Biophys ResCommun2002;294:161–166.
[51]韩霞,王建春,王曙霞,惠汝太.心肌细胞自身抗体的研究进展.中国分子心脏病学杂志,2005,5(6):813-817.
[52] Gohlke H, Albus C, Gysan DB, Hahmann HW, Mathes P; ESC. Cardiovascularprevention in clinical practice (ESC and German guidelines2007). Herz2009;34:4-14.
[53] Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol1991;68:28B–35B.
[54] Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in suddencardiac ischemic death. N Engl J Med1984;310:1137–1140.
[55] Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, Masuyama T, Kitabatake A,Minamino T. Lack of myocardial perfusion immediately after successful thrombolysis.A predictor of poor recovery of left ventricular function in anterior myocardialinfarction. Circulation1992;85:1699-1705.
[56] van't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of12-leadelectrocardiogram after successful reperfusion therapy for acute myocardial infarction.Zwolle Myocardial Infarction Study Group. Lancet1997;350:615-619.
[57] Iliceto S, Marangelli V, Marchese A, Amico A, Galiuto L, Rizzon P. Myocardialcontrast echocardiography in acute myocardial infarction: pathophysiologicalbackground and clinical application. Eur Heart J1996;17:344-353.
[58] van 't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F.Angiographic assessment of myocardial reperfusion in patients treated with primaryangioplasty for acute myocardial infarction. Myocardial Blush Grade. Circulation1998;97:2302-2306.
[59] Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction:underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol2010;55:1649-1660.
[60] Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am CollCardiol2009;54:281–292.
[61] De Luca G, van 't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH,Zijlstra F, de Boer MJ, Suryapranata H. Unsuccessful reperfusion in patients withST-segment elevation myocardial infarction treated by primary angioplasty. Am HeartJ2005;150:557–562.
[62] Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F. Rationalefor intracoronary administration of abciximab. J ThrombThrombolysis.2007;23:57–63.
[63] Kouz R, Kouz S, Schampaert E, Rinfret S, Tardif JC, Nguyen M, Eisenberg M,Harvey R, Afilalo M, Lauzon C, Dery JP, Mansour S, Huynh T. Effectiveness andsafety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarctionundergoing primary percutaneous coronary intervention: A meta-analysis ofobservational studies. Int J Cardiol2011Dec15;153(3):249-55.
[64] Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis ofclinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonistsfor percutaneous coronary intervention.Can J Cardio2007;23:963-970.
[65] De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Vande Werf F, Antman EM, Topol EJ. Abciximab as adjunctive therapy to reperfusion inacute ST-segment elevation myocardial infarction: a meta-analysis of randomizedtrials. JAMA2005293:1759–1765
[66] Randomised placebo-controlled trial of effect of eptifibatide on complications ofpercutaneous coronary intervention: IMPACT-II. Integrilin to Minimise PlateletAggregation and Coronary Thrombosis-II.Lancet1997;349:1422–1428.
[67] The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade withtirofiban on adverse cardiac events in patients with unstable angina or acutemyocardial infarction undergoing coronary angioplasty. Randomized Efficacy Studyof Tirofiban for Outcomes and REstenosis. Circulation1997;96:1445-1453.
[68] Jahns R, Boivin V, Schwarzbach V, Ertl G, Lohse MJ. Pathological autoantibodies incardiomyopathy. Autoimmunity.2008;6:454–461.
[69] Caforio AL, Mahon NG, Baig MK, Tona F, Murphy RT, Elliott PM, McKenna WJ.Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodiespredict disease development in asymptomatic relatives. Circulation.2007;1:76-83.
[70] Felix SB,Staudt A. Non-specific immunoadsorption in patients with dilatedcardiomyopathy: mechanisms and clinical effects. Int J Cardiol.2006;1:30-33.
[71] Doesch AO, Mueller S, Nelles M, Konstandin M, Celik S, Frankenstein L, Goeser S,Kaya Z, Koch A, Zugck C,Katus HA. Impact of troponin I-autoantibodies in chronicdilated and ischemic cardiomyopathy. Basic Res Cardiol.2011;1:25-35.
[72] Wallukat G. The beta-adrenergic receptors. Herz.2002;7:683–690.
[73] Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors inhuman idiopathic dilated cardiomyopathy. Circ Res.1989;1:97–103.
[74] Magnusson Y, Marullo S, Hoyer S, Waagstein F, Andersson B, Vahlne A, Guillet JG,Strosberg AD, Hjalmarson A, Hoebeke J. Mapping of a functional autoimmuneepitope on the beta1-adrenergic receptor in patients with idiopathic dilatedcardiomyopathy. J Clin Invest.1990;5:1658–1663.
[75] Liu HR, Zhao RR, Jiao XY, Wang YY, Fu M. Relationship of myocardial remodelingto the genesis of serum autoantibodies to cardiac beta(1)-adrenoceptors andmuscarinic type2acetylcholine receptors in rats. J Am Coll Cardiol.2002;11:1866–1873.
[76] Mobini R，Fu M，Wallukat G. A monoclonal anitibody directed against an，autoimmune epitope on the human betal-adrenergic receptor，recognized in iniopathinin dilated cardiomyopathy. Hybridoma，2000，19(2):135-142.
[77] Wallukat G，Wollenberger A，Morwinski R，etal.Anti-beta l-adrenocepter autoanbodieswith chronotropie activity from the serum of patients with dilated cardiomyopathy:mapping of epitopes in the first and second extracellar loops.J Mol cell Cardiol，1995，27(l):397-406.
[78] Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, Takahashi T, OgawaS. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptorsinduces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo.Circ Res.2001;6:578–586.
[79] Jahns R，Boivin V，Siegmund C， Inselmann G, Lohse MJ, Boege F. Autoantibodiesactivating human beta1-adrenergic receptors are associated with reduced cardiacfunction in chronic heart failure. Circulation,1999,99(5):649-654．
[80] Fukuda Y, Miyoshi S, Tanimoto K, Oota K, Fujikura K, Iwata M, Baba A, HagiwaraY, Yoshikawa T, Mitamura H, Ogawa S. Autoimmunity against the second extracellularloop of beta(1)-adrenergic receptors induces early afterdepolarization and decreases inK-channel density in rabbits. J Am Coll Cardiol2004Mar17;43(6):1090-100.
[81] Staudt Y，Mobini R，Fu M，Felix SB, Kühn JP, Staudt A．Beta1-adrenoceptor antibodiesinduce apoptosis in adult isolated cardiomyocytes． Eur J Phar-macol,2003,466(2):1-6．
[82] Deubner N, Berliner D, Schlipp A, Gelbrich G, Caforio AL, Felix SB, Fu M, Katus H,Angermann CE, Lohse MJ, Ertl G, Stork S, Jahns R. Cardiac beta1-adrenoceptorautoantibodies in human heart disease: rationale and design of the Etiology,Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail.2010;7:753–762.
[83] Di LA, Remme WJ, Charlesworth A, Cleland JG, Lutiger B, Metra M, Komajda M,Torp-Pedersen C, Scherhag A, Swedberg K, Poole-Wilson PA. Exchange ofbeta-blockers in heart failure patients. Experiences from the poststudy phase ofCOMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail.2005;4:640–649.
[84] Jahns R, Schlipp A, Boivin V, Lohse MJ. Targeting receptor antibodies in immunecardiomyopathy. Semin Thromb Hemost.2010;2:212–218.
[85] Greenberg B. Nonselective versus selective beta-blockers in the management ofchronic heart failure: clinical implications of the carvedilol or Metoprolol EuropeanTrial. Rev Cardiovasc Med.2004;5: S10–S17.
[86] Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Baba A, Anzai T, Meguro T, SatohT, Ogawa S. A pilot study on the role of autoantibody targeting the beta1-adrenergicreceptor in the response to beta-blocker therapy for congestive heart failure. J CardFail.2009;3:224–232.
[87] Fu ML. Anti-peptide antibodies against an autoimmune epitope on human muscarinicreceptor mimic functional autoantibodies against the same epitope in patients withidiopathic dilated cardiomyopathy. Eur Heart J.1995Dec;16Suppl O:89-91.
[88] Fu LX, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, HoebekeJ. Localization of a functional autoimmune epitope on the muscarinic acetylcholinereceptor-2in patients with idiopathic dilated cardiomyopathy. J Clin Invest.1993;5:1964–1968.
[89] Matsui S, Fu ML, Shimizu M, Fukuoka T, Teraoka K, Takekoshi N, Murakami E,Hjalmarson A. Dilated cardiomyopathy defines serum autoantibodies againstG-protein-coupled cardiovascular receptors. Autoimmunity.1995;2:85–88.
[90] Fu ML, Hoebeke J, Matsui S, Matoba M, Magnusson Y, Hedner T, Herlitz H,Hjalmarson A. Autoantibodies against cardiac G-protein-coupled receptors definedifferent populations with cardiomyopathies but not with hypertension. Clin ImmunolImmunopathol.1994;1:15–20.
[91] Matsui S, Fu ML, Katsuda S, Hayase M, Yamaguchi N, Teraoka K, Kurihara T,Takekoshi N, Murakami E, Hoebeke J, Hjalmarson A. Peptides derived fromcardiovascular G-protein-coupled receptors induce morphological cardiomyopathicchanges in immunized rabbits. J Mol Cell Cardiol.1997;2:641–655.
[92] Hernandez CC，Barcellos LC，Gimenez LE，et al． Human chagasic IgGs bind tocardiac muscarinic receptors and impair L-type Ca2+currents．Cardiovasc Res,2003,58(1):55-65．
[93] Akiyasu B，Tsutom U，Yoshikawa，et al． Autoantibddies against M2-muscarinicacetylcholine receptors: new upstream targets in atrial fibrillationin patients withdilated cardiomyopathy．European Heart Joumal,2004,25(3):1107-1115．
[94] Chiale PA, Ferrari I, Mahler E, Vallazza MA, Elizari MV, Rosenbaum MB, Levin MJ.Differential profile and biochemical effects of antiautonomic membrane receptorantibodies in ventricular arrhythmias and sinus node dysfunction. Circulation2001;103:1765-1771.
[95] Stavrakis S, Kem DC, Patterson E, Lozano P, Huang S, Szabo B, Cunningham MW,Lazzara R, Yu X. Opposing cardiac effects of autoantibody activation ofbeta-adrenergic and M2muscarinic receptors in cardiac-related diseases. Int J Cardiol.2011;3:331–336.
[96] Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S,Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy inPD-1receptor-deficient mice. Science.2001;5502:319–322.
[97] Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H,Matsumori A, Minato N, Honjo T. Autoantibodies against cardiac troponin I areresponsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med.2003;12:1477–1483.
[98] Goser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Ottl R, Zittrich S, Blaudeck N,Hardt SE, Pfitzer G, Rose NR, Katus HA, Kaya Z. Cardiac troponin I but not cardiactroponin T induces severe autoimmune inflammation in the myocardium. Circulation.2006;16:1693–1702.
[99] Kaya Z, Goser S, Buss SJ, Leuschner F, Ottl R, Li J, Volkers M, Zittrich S, Pfitzer G,Rose NR, Katus HA. Identification of cardiac troponin I sequence motifs leading toheart failure by induction of myocardial inflammation and fibrosis. Circulation.2008;20:2063–2072.
[100] Leuschner F, Li J, Goser S, Reinhardt L, Ottl R, Bride P, Zehelein J, Pfitzer G,Remppis A, Giannitsis E, Katus HA, Kaya Z. Absence of auto-antibodies againstcardiac troponin I predicts improvement of left ventricular function after acutemyocardial infarction. Eur Heart J.2008;16:1949–1955.
[101] Miettinen KH, Eriksson S, Magga J, Tuomainen P, Kuusisto J, Vanninen EJ, TurpeinenA, Punnonen KR, Pettersson K, Peuhkurinen KJ. Clinical significance of troponin Iefflux and troponin autoantibodies in patients with dilated cardiomyopathy. J Card Fail.2008;6:481–488.
[102] Mercadier JJ, Bouveret P, Gorza L, Schiaffino S, Clark WA, Zak R, Swynghedauw B,Schwartz K. Myosin iso enzymes in normal and hypertrophied human ventricularmyocardium. Circ Res.1983;1:52–62.
[103] Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiacmyosin induces myocarditis in genetically predisposed mice. J Immunol.1987;11:3630–3636.
[104] Neumann DA, Rose NR, Ansari AA, Herskowitz A. Induction of multiple heartautoantibodies in mice with coxsackievirus B3-and cardiac myosin-inducedautoimmune myocarditis. J Immunol.1994;1:343–350.
[105] Lauer B, Padberg K, Schultheiss HP, Strauer BE. Autoantibodies against humanventricular myosin in sera of patients with acute and chronic myocarditis. J Am CollCardiol.1994;1:146–153.
[106] Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ,Schiaffino S. Identification of alpha-and beta-cardiac myosin heavy chain isoforms asmajor autoantigens in dilated cardiomyopathy. Circulation.1992;5:1734–1742.
[107] Lauer B, Schultheiss HP, Padberg K. Autoantibodies against cardiac myosin inpatients with myocarditis and dilated cadriomyopathy. Z Kardio,1995,84(4):301-310.
[108] Kuan AP, Chamberlain W, Malkiel S, Lieu HD, Factor SM, Diamond B, Kotzin B.Genetic control of autoimmune myocarditis mediated by myosin-specific antibodies.Immunogenetics.1999;2:79–85.
[109] Kuan AP, Zuckier L, Liao L, Factor SM, Diamond B. Immunoglobulin isotypedetermines pathogenicity in antibody-mediated myocarditis in naive mice. Circ Res.2000;3:281–285.
[110] Warraich RS, Noutsias M, Kazak I, Seeberg B, Dunn MJ, Schultheiss HP, Yacoub MH,Kuhl U. Immunoglobulin G3cardiac myosin autoantibodies correlate with leftventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3and clinical correlates. Am Heart J.2002;6:1076–1084.
[111] Warraich RS, Griffiths E, Falconar A, Pabbathi V, Bell C, Angelini G, Suleiman MS,Yacoub MH. Human cardiac myosin autoantibodies impair myocyte contractility: acause-and-effect relationship. FASEB J.2006;6:651–660.
[112] Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry andantibody-mediated cell signaling in autoimmune myocarditis. J Immunol.2006;11:8234–8240.
[113] Saito S, Hiroi Y, Zou Y, Aikawa R, Toko H, Shibasaki F, Yazaki Y, Nagai R, Komuro I.beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiacmyocytes. J Biol Chem.2000;44:34528–34533.
[114] Lv H, Havari E, Pinto S, Gottumukkala RV, Cornivelli L, Raddassi K, Matsui T,Rosenzweig A, Bronson RT, Smith R, Fletcher AL, Turley SJ, Wucherpfennig K,Kyewski B, Lipes MA. Impaired thymic tolerance to alpha-myosin directsautoimmunity to the heart in mice and humans. J Clin Invest.2011;4:1561–1573.
[115] Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in thethymus for positive selection and central tolerance induction. Nat Rev Immunol.2009;12:833–844.
[116] Berg PA, Klein R. Mitochondrial antigens and autoantibodies: from anti-M1toanti-M9. Klin Wochenschr.1986;19:897–909.
[117] Klein R, Maisch B, Kochsiek K, Berg PA. Demonstration of organ specific antibodiesagainst heart mitochondria (anti-M7) in sera from patients with some forms of heartdiseases. Clin Exp Immunol.1984;2:283–292.
[118] Bottazzo GF, Todd I, Mirakian R, Belfiore A, Pujol-Borrell R. Organ-specificautoimmunity: a1986overview. Immunol Rev.1986;94:137–169.
[119] Schultheiss HP, Schwimmbeck P, Bolte HD, Klingenberg M. The antigeniccharacteristics and the significance of the adenine nucleotide translocator as a majorautoantigen to antimitochondrial antibodies in dilated cardiomyopathy. AdvMyocardiol.1985;6:311-327.
[120] Kuhl U, Melzner B，Schafer B, etal.The Ca-channel as cardiac autoantigen. Eur HeartJ,1991,12suppl D:99-104.
[121] Schultheiss HP, Bolte HD. Immunological analysis of auto-antibodies against theadenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol.1985;17:603–617.
[122] Maack C, O’ Rourke B. Excitation-contraction coupling and mitochondrial energetics.Basic Res Cardiol,2007,102(5):369-392.
[123] Schulze K, Witzenbichler B, Christmann C, Schultheiss HP. Disturbance ofmyocardial energy metabolism in experimental virus myocarditis by antibodies againstthe adenine nucleotide translocator. Cardiovasc Res.1999;1:91–100.
[124] Liao YH，Yuan J，Wang ZH，Cheng X, Zhang JH, Tian Y, Dong JH, Guo HP, Wang M.Infectious tolerance to ADP/ATP carrier peptides induced by anti-L3T4monoclonalantibody indilated cardiomyopathy mice. J Clin Immuno，2005，25(4):376-384.
[125] Mobini R, Maschke H, Waagstein F.New insights into the pathogenesis of dilatedcardiomyopathy: possible underlying autoimmune mechanisms and therapy.Autoimmun Rev.2004Jun;3(4):277-84.
[126] Manchado C, Orus J, Villarroya F, Roig E, Heras M, Giralt M, Iglesias R, Sanz G,Mampel T, Vinas O. Epitope mapping of mitochondrial adenine nucleotide translocase-1in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol.2002;5:571–582.
[127] Andreoletti L, Leveque N, Boulagnon C, Brasselet C, Fornes P. Viral causes ofhuman myocarditis. Arch Cardiovasc Dis.2009;6–7:559–568.
[128] Schulze K, Heineman FW, Schultheiss HP, Balaban RS. Impairment of myocardialcalcium homeostasis by antibodies against the adenine nucleotide translocator. CellCalcium.1999;5:361–370.
[129] Michels VV，Moll PP，Rodeheffer RJ et al.Circulating heart autoantibodies in familialas compared with nofamilial idiopathic dilated cardiomyopathy. Mayo Clin Proc,1994,69(1):24-27.
[130] Takemoto M，Kusachi S, Urabe N, Inoue K, Tsuji T. Auto-antibody against adeninenucleotide translocator in dilated cardiomyopathy and myocarditis-incidence andrelation to cardiac function and morphology. Jpn Circ J,1993,57(12):1150-1158.
[131] Norgaard A, Bagger JP, Bjerregaard P, Baandrup U, Kjeldsen K, Thomsen PE.Relation of left ventricular function and Na,K-pump concentration in suspectedidiopathic dilated cardiomyopathy. Am J Cardiol.1988;15:1312–1315.
[132] Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmalNa-K-ATPase: possible upstream targets of arrhythmias and sudden death in patientswith dilated cardiomyopathy. J Am Coll Cardiol.2002;6:1153–1159.
[133] Baba A, Yoshikawa T, Iwata M, Anzai T, Nakamura I, Wainai Y, Ogawa S, Fu M.Antigen-specific effects of autoantibodies against sarcolemmal Na-K-ATPase pump inimmunized cardiomyopathic rabbits. Int J Cardiol.2006;1:15–20.
[134] Winrow VR, McLean L, Morris CJ, Blake DR. The heat shock protein response andits role in inflammatory disease. Ann Rheum Dis.1990;2:128–132.
[135] Latif N, Smith J, Dunn MJ, Yacoub MH, Rose ML. Complement-mediated cytotoxicactivity of anti-heart antibodies present in the sera of patients with dilatedcardiomyopathy. Autoimmunity.1994;2:99–104.
[136] Lin L, Kim SC, Wang Y, Gupta S, Davis B, Simon SI, Torre-Amione G, Knowlton AA.HSP60in heart failure: abnormal distribution and role in cardiac myocyte apoptosis.Am J Physiol Heart Circ Physiol.2007;4: H2238–H2247.
[137] Ching YP, Qi Z, Wang JH. Cloning of three novel neuronal Cdk5activator bindingproteins.Gene2000;242:285–294.
[138]陈敬洲,韩玉,张银辉,等. IC53基因超表达改变系列心衰相关基因表达水平.中国分子心胜病学杂志,2005,5(1):401-404.
[139] Bkaily G, El-Bizri N, Bui M, Sukarieh R, Jacques D, Fu ML.Modulation ofintracellular Ca2+via L-type calcium channels in heart cells by the autoantibodydirected against the second extracellular loop of the alpha1-adrenoceptors. Can JPhysiol Pharmacol.2003Mar;81(3):234-246.
[140]陈敬洲,韩玉,张银辉,等. IC53基因在血管及动脉粥样硬化斑块中的表达谱分析.中国分子心胜病学杂志,2005,5(3):523-524.
[141]韩霞,亓维东,陈敬洲,惠汝太,张志强,张增堂.心力衰竭患者中IC53基因自身抗体的研究.临床心血管病杂志2011,27(4):263-267.
[142] Wallukat G, Reinke P, Dorffel WV, Luther HP, Bestvater K, Felix SB, Baumann G.Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int JCardiol.1996;2:191-195.
[143] Cooper LT, Belohlavek M,Korinek J,Yoshifuku S, Sengupta PP, Burgstaler EA,Winters JL. A pilot study to assess the use of protein a immunoadsorption for chronicdilated cardiomyopathy. J Clin Apher.2007;4:210-214.
[144] Knebel F, Bohm M, Staudt A, Borges AC, Tepper M, Jochmann N, Wernicke KD,Felix S, Baumann G. Reduction of morbidity by immunoadsorption therapy in patientswith dilated cardiomyopathy. Int J Cardiol.2004;3:517-520.
[145] Staudt A, Hummel A, Ruppert J, Dorr M, Trimpert C, Birkenmeier K, Krieg T, StaudtY, Felix SB. Immunoadsorption in dilated cardiomyopathy:6-month results from arandomized study. Am Heart J.2006;4:712-716.
[146] Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S,Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G. Hemodynamiceffects of immunoadsorption and subsequent immunoglobulin substitution in dilatedcardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol.2000;6:1590-1598.
[147] Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K, Wallukat G,Wernecke KD, Stangl K, Baumann G, Felix SB Immunohistological changes in dilatedcardiomyopathy induced by immunoadsorption therapy and subsequentimmunoglobulin substitution. Circulation.2001;22:2681-2686.
[148] Anderson JL, Carlquist JF, Lutz JR, DeWitt CW, Hammond EH. HLA A, B and DRtyping in idiopathic dilated cardiomyopathy: a search for immune response factors.Am J Cardiol.1984;9:1326-1330.
[149] Harcombe AA, Sharples L, Large SR, Wallwork J, Weissberg PL, Joysey V. HLAantigen frequencies in end-stage idiopathic and ischaemic cardiomyopathy. Int JCardiol.1999;1::31-37.
[150] Kallwellis-Opara A, Staudt A, Trimpert C, Noutsias M, Kuhl U, Pauschinger M,Schultheiss HP, Grube M, Bohm M, Baumann G, Volker U, Kroemer HK, Felix SB.Immunoadsorption and subsequent immunoglobulin substitution decreases myocardialgene expression of desmin in dilated cardiomyopathy. J Mol Med.2007;12:1429–1435.
[151] Orozco AF, Lewis DE. Flow cytometric analysis of circulating microparticles inplasma. Cytometry A.2010;6:502–514.
[152] Nozaki T, Sugiyama S, Sugamura K, Ohba K, Matsuzawa Y, Konishi M, Matsubara J,Akiyama E, Sumida H, Matsui K, Jinnouchi H, Ogawa H. Prognostic value ofendothelial microparticles in patients with heart failure. Eur J Heart Fail.2010;11:1223–1228.
[153] Bulut D, Scheeler M, Niedballa LM, Miebach T, Mugge A. Effects ofimmunoadsorption on endothelial function, circulating endothelial progenitor cells andcirculating microparticles in patients with inflammatory dilated cardiomyopathy. ClinRes Cardiol.2011;100:603–610.
[154] Mobini R, Staudt A, Felix SB, Baumann G, Wallukat G, Deinum J, Svensson H,Hjalmarson A, Fu M. Hemodynamic improvement and removal of autoantibodiesagainst beta1-adrenergic receptor by immunoadsorption therapy in dilatedcardiomyopathy. J Autoimmun.2003;4:345–350.
[155] Torre-Amione G, Sestier F, Radovancevic B, Young J. Broad modulation of tissueresponses (immune activation) by celacade may favorably influence pathologicprocesses associated with heart failure progression. Am J Cardiol.2005Jun6;95(11A):30C-37C.
[156] Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P,Keren A, Motro M, Moyé LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleau JL,Sestier F, Winkelmann BR, Young JB; Advanced Chronic Heart Failure ClinicalAssessment of Immune Modulation Therapy InvestigatorsResults of a non-specificimmunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet.2008Jan19;371(9608):228-36..
[157] Tepliakov AT, Bolotskaia LA, Stepacheva TA, Karaman NV, Rybal'chenko EV, ShilovSN, Maslov AP. Kardiologiia. Suppressive effect of recombinant immunomodulatorronkoleukin on the blood level of antiinflammatory cytokines, anticardiolipinautoantibodies and heart failure.2008;48(8):34-40.
[158] Aukrust P, Yndestad A, Ueland T, Damas JK, Froland SS, Gullestad L. The role ofintravenous immunoglobulin in the treatment of chronic heart failure. Int J Cardiol.2006;1:40–45.
[159] Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S,Kjekshus J, Nitter-Hauge S,Ueland T, Lien E, Froland SS, Aukrust P.Immunomodulating therapy with intravenous immunoglobulin in patients with chronicheart failure. Circulation.2001;2:220–225.
[160] Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection:evolutionary and therapeutic implications. Nat Rev Immunol.2010;5:328–343.
[161] Larsson L, Mobini R, Aukrust P, Gullestad L, Wallukat G, Waagstein F, Fu M.Beneficial effect on cardiac function by intravenous immunoglobulin treatment inpatients with dilated cardiomyopathy is not due to neutralization of anti-receptorautoantibody. Autoimmunity.2004;6–7:489–493.
[162] Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Baba A, Anzai T, Meguro T, SatohT, Ogawa S. A pilot study on the role of autoantibody targeting the beta1-adrenergicreceptor in the response to beta-blocker therapy for congestive heart failure. J CardFail.2009Apr;15(3):224-32.
[163] Chen J, Hu DY, Zhang L, Liu XL, Wu YF, Li J. The effect of carvedilol on cardiacfunction and autoantibodies against the cardiac receptors. Zhonghua Xin Xue GuanBing Za Zhi.2005Jun;33(6):498-501.
[164] Miao GB, Liu JC, Liu MB, Wu JL, Zhang G, Chang J, Zhang L. Autoantibody againstbeta1-adrenergic receptor and left ventricular remodeling changes in response tometoprolol treatment. Eur J Clin Invest.2006Sep;36(9):614-20.
[165] Lippi G, Montagnana M, Danese E, Favaloro EJ, Franchini M. Glycoprotein IIb/IIIainhibitors: an update on the mechanism of action and use of functional testing methodsto assess antiplatelet efficacy. Biomark Med2011;5:63-70.
[166] Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, JordanRE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab:Dispersal of newly formed platelet aggregates. Thromb Haemost2002;87:1020–1025.
[167] Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria C. Disaggregation ofinvitro preformed platelet-rich clots by abciximab increases fibrin exposure andpromotes fibrinolysis. Arterioscler Thromb Vasc Biol2001;21:142–148.
[168] Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared tointravenous abciximab in patients with acute coronary syndromes undergoing percutaneouscoronary intervention: a systematic review and meta-analysis. J Invasive Cardiol2010;22:278-282.
[169] Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality ofreports of meta-analyses of randomised controlled trials: the QUOROM statement.Quality of Reporting of Meta-analyses. Lancet1999;354:1896–1900.
[170] Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Doesquality of reports of randomized trials affect estimates of intervention efficacyreportedin meta-analyses? Lancet1998;352:609–613.
[171] Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials1986;7:177–88.
[172] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ2003;327:557–560.
[173] Bertrand OF, Rodés-Cabau J, Larose E, Nguyen CM, Déry JP, Proulx G, Roy L, PoirierP, Costerousse O, De Larochellière R. Effects of intracoronary compared to intravenousabciximab administration in patients undergoing transradial percutaneous coronaryintervention: A sub-analysis of the EASY trial. Int J Cardio2009;136:165-170.
[174] Kakkar AK, Moustapha A, Hanley HG, Weiss M, Caldito G, Misra P, Reddy PC, Tandon N.Comparison of intracoronary vs. intravenous administration of abciximab in coronarystenting. Catheterization and Cardiovascular Interventions2004;61:31-34.
[175] Erdim R, Erciyes D, G rmez S, Karabay KO, Catako lu AB, Aytekin V, Demiro lu C, GülbaranM. Comparison of intracoronary versus intravenous administration of tirofiban inprimary percutaneous coronary intervention. Anadolu Kardiyol Derg2010;10:340-345.
[176] W hrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, Hombach V, H her M.Reduction of major adverse cardiac events with intracoronary compared withintravenous bolus application of abciximab in patients with acute myocardialinfarction or unstable angina undergoing coronary angioplasty. Circulation2003;107:1840-1843.
[177] Lee CH, Ngo HM, Sewianto A, et al. Comparison between fixed-dose, intracoronarybolus-only versus standard weight-adjusted dose, intravenous bolus and infusionadministration of abciximab in patients undergoing primary percutaneous coronaryintervention. Int J Cardion2010;145:355-357.
[178] Romagnoli E, Burzotta F, Trani C, Mazzari MA, Biondi-Zoccai GG, De Vita M, GiannicoF, Niccoli G, Prati F, Rebuzzi AG, Mongiardo R, Crea F. Angiographic evaluation of theeffect of intracoronary abciximab administration in patients undergoing urgent PCI.Int J Cardiol2005;105:250-255.
[179] K rma C, Erkol A, Pala S, Oduncu V, Dündar C, zgi A, Tigen K, Gibson CM. Intracoronarybolus-only compared with intravenous bolus plus infusion of tirofiban application inpatients with ST-elevation myocardial infarction undergoing primary percutaneouscoronary intervention. Catheter Cardiovasc Interv2011.
[180] Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronaryeptifibatide bolus administration during percutaneous coronary revascularization foracute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptoroccupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.Circulation2010;121:784-791.
[181] Wu TG, Zhao Q, Huang WG, Wei JR, Chen SW, Zhao J, Huang LP, Wang LX. Effect ofIntracoronary Tirofiban in Patients Undergoing Percutaneous Coronary Interventionfor Acute Coronary Syndrome. Circ J2008;72:1605–1609.
[182] Yang XC, Zhang DP, Wang LF, Xu L, Ge YG, Wang HS, Li WM, Ni ZH, Xia K, Lian Y, XueYL, Ma LX. Effects of intracoronary or intravenous tirofiban administration in patientswith acute ST-elevation myocardial infarction undergoing primary percutaneouscoronary intervention. Zhong hua Xin Xue Guan Bing Za Zhi2007Jun;35:517-522.
[183] Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, PedersenS, Jensen KS, Jensen JS. Intracoronary compared to intravenous bolus abciximab duringprimary percutaneous coronary intervention in ST-segment elevation myocardialinfarction (STEMI) patients reduces30-day mortality and target vesselrevascularization: A randomized trial. J Interv Cardiol2011;24:105-111.
[184] Gu YL, Kampinga MA, Wieringa WG, et al. Hansen PR, Galatius S, Madsen JK, EngstroemT, Pedersen S, Jensen KS, Jensen JS.
[185] Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A,M bius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolusabciximab application in patients with ST-elevation myocardial infarction undergoingprimary percutaneous coronary intervention. The randomized leipzig immediatepercutaneous coronary intervention abciximab IV versus IC in ST-elevationmyocardial infarction trial. Circulation2008;118;49-57.
[186] Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Gaudreault V, Proulx G, Barbeau G, DéryJP, Gleeton O, Manh-Nguyen C, No l B, Roy L, Costerousse O,De Larochellière R; EArlyDischarge after Transradial Stenting of CoronarY Arteries in Acute MyocardialInfarction (EASY-MI) Study Investigators. Intracoronary compared to intravenousabciximab and high-dose bolus compared to standard dose in patients withST-segment elevation myocardial infarction undergoing transradial primarypercutaneous coronary intervention: a two-by-two factorial placebo-controlledrandomized study. Am J Cardio2010;105:1520-1527.
[187] Thiele H, W hrle J, Neuhaus P, et al. Intracoronary compared with intravenous bolusabciximab application during primary percutaneous coronary intervention: AIDASTEMI trial.2011Late-Breaking Clinical Trial/Clinical Science: Special ReportsAbstracts. Circulation2011;124:2365-2374.
[188] Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P, Bosa-Ojeda F, Samimi-Fard S,Marrero-Rodriguez F, Kaski JC. Intracoronary versus intravenous abciximabadministration in patients with ST-elevation myocardial infarction undergoingthrombus aspiration during primary percutaneous coronary intervention-Effects onsoluble CD40ligand concentrations. Atherosclerosis2009;206:523-527.
[189] Eitel I, Friedenberger J, Fuernau G, Dumjahn A, Desch S, Schuler G, Thiele H. Intracoronaryversus intravenous bolus abciximab application in patients with ST-elevationmyocardial infarction undergoing primary percutaneous coronary intervention:6-month effects on infarct size and left ventricular function. Clin Res Cardiol2011;100:425-32.
[190] Galache Osuna JG, Sánchez-Rubio J, Calvo I, Diarte JA, Lukic A, Placer LJ. Doesintracoronary abciximab improve the outcome of percutaneous coronary interventions?A randomized controlled trial. Rev Esp Cardiol2006;59:567-74.
[191] Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP. Increase of myocardial salvageand left ventricular function recovery with intracoronary abciximab downstream of thecoronary occlusion in patients with acute myocardial infarction treated with primarycoronary intervention. Catheter Cardiovasc Interv2004;62:186-192.
[192] Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoproteinIIb/IIIa inhibitors. J Interv Cardiol2002;15:45–60.
[193] Moser M, Bertram U, Peter K, Bode C, Ruef J. Abciximab, eptifibatide, and tirofibanexhibit dose-dependent potencies to dissolve platelet aggregates. J CardiovascPharmacol.2003;41:586–592.
[194] Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GB.A monoclonal antibody againstthe platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation andthrombosis in a canine model of coronary angioplasty. Circulation1991;84:2463–2469.
[195] Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo plateletthrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIareceptor: correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation1989;80:1766–1774.
[196] Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE,Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: dispersal ofnewly formed platelet aggregates. Thromb Haemost2002;87:1020-1025.
[197] Kumar A, Herrmann HC. Tirofiban: an investigational platelet glycoprotein IIb/IIIareceptor antagonist. Expert Opin Investig Drugs1997;6:1257-1267.
[198] Hansen RJ, Balthasar JP. Pharmacokinetics, pharmacodynamics, and platelet bindingof an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative ratmodel of immune thrombocytopenic purpura. J Pharmacol Exp Ther2001;298:165-171.
[199] Scarborough RM. Development of eptifibatide. Am Heart J1999;138:1093-104.
[200] Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, WeismanHF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrinanti-platelet antibody Fab7E3in high risk coronary angioplasty. Circulation1994;90:1757–1764.
[201] Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE.Pharmacodynamic profile of short-term abciximab treatment demonstrates prolongedplatelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade.Circulation1998;97:1680–1688.
[202] Topol EJ, Byzova T, Plow EF. Of platelets, integrin αIIbβ3and GPIIb–IIIa blockers:past, present and future perspectives. Lancet1999;353:227–231.
[203] Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER. A comparison ofabciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoingprimary percutaneous coronary intervention. A meta-analysis of contemporaryrandomized controlled trials. Circ Cardiovasc Interv2009;2:230-236.
[204] Amborse JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographicevalution of coronary artery morphology in unstable angina. J Am Coll Cardiol7:472-78,1986.
[205] Falk E. Morphologic features of unstable atherothrombotic plaques underlying acutecoronary syndromes. Am J Cardiol63:114E-120E,1989.
[206] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary arterydisease and the acute coronary syndromes. N Engl J Med326:242-250,1992.
[207] Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, NakamuraH, Ambrose JA. Angioscopic evaluation of coronary syndromes. N Engl J Med326:287-291,1992.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |